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ABSTRACT
THERAPEUTIC EFFICACY OF CERIUM OXIDE NANOPARTICLES AGAINST SEPSIS INDUCED
MULTI-ORGAN DYSFUNCTION SYNDROME AND DEATH IN SPRAGUE DAWLEY RATS

Sepsis is a generalized term that signifies the presence of a pathogen in the blood
stream to which the body responds by eliciting a systemic inflammatory response. Although
sepsis is the leading cause of death in non-coronary intensive care units in United States, there
are currently no FDA approved therapeutic drugs to treat this disorder. Cerium oxide
nanoparticles (CeO2) have been shown to exhibit anti-oxidant, anti-inflammatory, and antibacterial properties both in vitro and in vivo. Whether CeO2 nanoparticles can be used for the
treatment of sepsis is currently unclear.
To investigate whether CeO2 nanoparticles can be used to treat moderate sepsis, twelve
week old male Sprague Dawley rats were randomly divided into one of four different groups:
control, CeO2 only, sepsis, and sepsis + CeO2. Moderate sepsis was induced by the
intraperitoneal injection of cecal material (400mg/kg). The CeO2 nanoparticle treated animals
received an intravenous injection of CeO2 nanoparticles (3.5mg/kg) at the time of sepsis
induction. Treatment significantly decreased sepsis induced mortality. Treatment associated
increases in animal survivability were associated with a significant decrease in serum IL-6,
growth regulated alpha protein (KC/GRO), macrophage inflammatory protein-1 beta (MIP-1 β)
macrophage derived chemokine (MDC), monocyte chemotactic protein-3 (MCP-3), myoglobin,
macrophage inflammatory protein-3 beta (MIP-3β), eotaxin, leptin, macrophage inflammatory
protein-2 (MIP-2), interferon gamma induced protein-10 (IP-10), tissue inhibitor of

xvi

metalloproteinases-1 (TIMP-1), plasminogen activator inhibitor-1 (PAI-1) and blood urea
nitrogen (BUN).
In an effort to further investigate whether there is a similar degree of response with
smaller size and dose of CeO2 nanoparticles on the attenuation of severe sepsis, twelve week
old male Sprague Dawley rats were randomly divided into one of four groups: control, CeO 2
only, sepsis and sepsis + CeO2. Severe sepsis was induced by the intraperitoneal injection of
cecal material (600mg/kg). The CeO2 nanoparticle treated animals received an intravenous
injection of CeO2 nanoparticles (0.5mg/kg) at the time of sepsis induction. Treatment with CeO 2
nanoparticles significantly decreased animal mortality and sepsis-induced hypothermia.
Treatment associated increases in animal survivability were associated with evidence of
diminished Erk 1/2 phosphorylation, Jak/Stat-3 activation, P-selectin levels and expression of
vascular cell adhesion molecule-1 (VCAM-1) in the heart. Changes in cardiac signaling appeared
to coincide with decreased serum IL-6, leukemia inhibitory factor, myoglobin and creatine
kinase. In the liver, CeO2 nanoparticle treatment reduced sepsis-induced increases in hepatic
superoxide levels, inducible nitric oxide synthase, and protein nitrosylation. Treatment
associated increases in liver function were accompanied by diminished levels of serum reactive
oxygen species (ROS) and several inflammatory markers.
CeO2 nanoparticles were also found to attenuate sepsis-induced renal damage by
preserving the renal brush border and attenuating the incidence of tubular dilatation. These
changes in kidney morphology were accompanied by decreases in levels of serum β-2
microglobulin, kidney injury molecule-1, cystatin-C, osteopontin, BUN, glucose, sodium, and
potassium. At the cellular level, CeO2 nanoparticles attenuated the sepsis-induced activation of
xvii

Stat-3 and the cleavage of caspase-3. Taken together the data from this current study indicate
that CeO2 nanoparticles can be used for the prevention of sepsis induced multi-organ
dysfunction syndrome and death. Additional studies using other sepsis models or interventional
time points may be warranted to determine the potential efficacy of using CeO 2 nanoparticles
to treat sepsis.

xviii

Chapter 1
Introduction
Sepsis is a pathological condition characterized by systemic inflammatory response
syndrome (SIRS) that is triggered by host immune system as a countermeasure to an infectious
agent in the blood [1]. Severe sepsis though curable when diagnosed early, can rapidly progress
to a medical emergency, multi-organ dysfunction and death if not treated properly. Sepsis is
not new. The term sepsis was first used by Hippocrates in the late 4th century BC to describe a
process by which flesh rotted and lead to a foul smell [2]. In the late 1800’s Louis Pasteur
discovered the link between microscopic organisms and infectious disease. Later on, Lister,
Lennhartz, Asbough and others demonstrated that sepsis does not necessarily develop due to
the presence of an infectious agent, but rather that it is the interaction between the host
immune system and the agent that initiates the onset. As we have learned more about this
disorder, the previously held notion of sepsis being primarily a disease of bacterial etiology has
begun to expand to also incorporate the complex multi-factorial interaction of the host immune
system.
Sepsis is the leading cause of death in non-coronary intensive care unit and ranks
among the top ten mortality causing diseases in United States [3]. It is estimated that sepsis is
responsible for ~60,000 deaths annually [4]. The costs for treating sepsis in 2008 alone were
almost $15 billion and are expected to increase by >10% in each passing year [5]. Clearly new
and better methods to treat this disorder are needed.

Sepsis is the systemic reaction to an over-activated immune system

Sepsis usually arises as a secondary medical condition to an already existing localized
infection of lungs, liver, kidney, or some other internal structure. When the localized infection
is left untreated, it can progress to the circulation and become systemic. A systemic infection
occurs when the blood becomes contaminated with bacteria. Once this occurs, the immune
system is set on high alert and may become over-activated which can result in the development
of the systemic inflammatory response syndrome (SIRS). If not properly managed, SIRS can
rapidly progress to sepsis, a state of multi-organ failure, sepsis shock and death. The molecular
events which govern the transition from infection to SIRS, sepsis, and death are not yet
understood although it is thought that the innate immune system may play a role.
Upon invasion of the pathogens into the blood stream, host immune cells such as the
circulating macrophages and neutrophils recognize the pathogen associated molecular patterns
(PAMP’s) that are present on the cell surface which elicit the release of several inflammatory
cytokines [6]. If this initial response overwhelms the invader, recovery usually ensues and there
are no further problems. However, if the initial response is not sufficient, the immune system
becomes further activated which can lead to the development of SIRS and sepsis.
The inflammatory cascade is characterized by the early release of tumor necrosis factor
–alpha and IL-1β that are thought to mediate the release of other pro-inflammatory cytokines
including IL-6, IL-12, HMGB1 and prostaglandins [7]. In addition to these inflammatory
mediators, the potent vasodilator nitric oxide is also released into circulation which can cause
severe hypotension [8]. Decreases in pressure can lead to diminished blood flow velocity, which
facilitates the interaction and binding of circulating macrophages and lymphocytes to
endothelial selectins and extravasation into the extracellular matrix [9]. Increased extravasation
2

in turn, can lead to tissue edema and impaired tissue oxygenation, tissue hypoxia and organ
dysfunction.
The early and accurate diagnosis of sepsis is a goal that has yet to be met. Sepsis
diagnosis is difficult due to the presence of several non-specific symptoms such as fever, rashes,
anorexia and weakness that make it difficult to differentiate from diseases with similar
symptoms until it is too late. The current first line treatment for sepsis is antibiotics but the
effectiveness of these agents is often hindered by the presence of inflammatory cytokines. As
such there is an immediate need for the development of new and better treatment modalities.
Cerium oxide has a fluorite lattice structure with vacant electrons in its outermost
orbital shells [10] which permits the cycling of ceria between its fully oxidized (Ce +4 ) and
reduced (Ce+3) states [11]. Although cerium oxide is currently used in the manufacture of sun
screens, polishing agents and as a fuel cell catalyst [12-14], recent studies have suggested that
this molecule could also be utilized for biomedical applications. For example, studies have
shown that CeO2 nanoparticles can protect cardiac progenitor cells from ROS induced oxidative
stress [15] and normal human breast cells from radiation-induced apoptotic cell death invitro
[16]. Similarly, others have shown that CeO2 nanoparticles can confer protection against carbon
tetrachloride-induced oxidative stress in mice [17]. It has been also been shown that CeO2
nanoparticles can act as an anti-bacterial agent by impairing the membrane integrity of E. coli
[18, 19].

Whether CeO2 nanoparticles can help to prevent sepsis induced multi-organ

dysfunction and death has to our knowledge, not been investigated.

3

Specific aims
Severe sepsis is characterized by a systemic inflammatory response that involves
complex interactions between the host immune system and the pathological agent that usually
results in a profound level of cellular damage to the host. Current treatment modalities are,
unfortunately, not beneficial during the advanced stages of sepsis. Recent studies in vitro and in
vivo have shown that CeO2 nanoparticles possess anti-bacterial, anti-inflammatory and antioxidant properties [20-22]. Whether CeO2 nanoparticles can be used to prevent sepsis induced
multi organ damage is not yet known.
The central focus of this current study is to determine whether CeO 2 nanoparticles can
attenuate sepsis induced organ damage and death in the laboratory rat. We hypothesize that
CeO2 nanoparticle treatment will be associated with diminished sepsis-induced organ damage,
which will result in improved animal survivability. This hypothesis will be tested by pursuing
the following three specific aims:
Specific Aim I: To determine whether CeO2 nanoparticles can attenuate the systemic
inflammatory response syndrome during septic insult in male Sprague Dawley rats.
Specific Aim II: To investigate if CeO2 nanoparticles can attenuate severe sepsis-induced
inflammatory damage to the heart and liver during a septic insult in male Sprague Dawley
rats.
Specific Aim III: To determine whether CeO2 nanoparticles can attenuate severe sepsisinduced inflammatory damage to the kidney during a septic insult in male Sprague Dawley
rats.
4

Chapter 2
2.1 Review of literature
A review of the pertinent literature concerning the present study will be
presented in this chapter. The following areas will be addressed: 1. Etiology and epidemiology
of sepsis, 2. Animal models of sepsis, 3. Pathophysiology of sepsis, and 4. Use of CeO2
nanoparticles for biomedical application.

2.2 Sepsis and systemic inflammatory response syndrome
Sepsis is characterized by a state of uncontrolled immune response to the presence of
an infectious agent or their toxic metabolites [23]. Sepsis usually begins with the entry of
pathogens or its toxins into the body. Upon entry, the host immune cells attempt to eliminate
the infectious agent by direct ingestion and destruction or by the secretion of antibodies that
bind to the pathogens making them targets to other host immune cells. During this process, the
cells of immune system also release cytokines that act in autocrine or paracrine fashion to
stimulate other cells. If the infection is not contained, cytokine release can proceed unabated
giving rise to systemic inflammation or a systemic inflammatory response syndrome (SIRS) [24]
(Figure 2-1). The diagnostic criteria for SIRS are:
1. An increase in core body temperature above 38.0 °C or decrease in core body
temperature below 36.0 °C.
2. An increase in heart rate or tachycardia > 90 beats/minute.
3. An increase in respiratory rate or tachypnea > 20 breaths/minute.
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4. An increase in number of white blood cells (WBC) > 12x109 cells/L or decrease in WBC <
4x109 cells/L.
Although sepsis is characterized by SIRS, one should carefully evaluate the symptoms of
disease as other pathological conditions including burns, cancer, pancreatitis can also give rise
to the SIRS. As such, the important criterion for the diagnosis of sepsis is the documented
presence of an infectious agent or its toxin.

Figure 2-1. Progression of sepsis

Source: https://my.vanderbilt.edu/sepsismonitor/progress-reports/

2.3 Etiology and epidemiology of sepsis
Sepsis is a complex disease of multifactorial etiology that can result in death within a
few hours to days depending on the immune status of the individual. Sepsis syndrome involves
characteristics of several diseases including hemorrhagic/hypovolemic shock, and ischemia.
6

Although the occurrence of sepsis has been known for over 3000 years, the etiology and
pathogenesis of sepsis is still not well understood [25].
Severe sepsis is one of the leading causes of death in United States and is the number
one cause of death in non-intensive care coronary units [26]. According to a recent report from
Center for Disease Control and Prevention, the incidence of sepsis has more than doubled over
the last decade likely because of increase in aging population with chronic illness or greater
increase in invasive surgical procedures, chemotherapy and immunosuppressive drugs. The
costs for treating sepsis rose from almost $15 billion in 2008 to over $20 billion in 2011 making
sepsis the most expensive disease to be billed to Medicare in 2011 [27]. Perhaps most telling,
sepsis is thought to account for 60-80% of all deaths in developing countries, which is almost 6
million deaths annually [28]. New and better methods to treat this disorder are clearly needed.

2.4 Animal models of sepsis
Understanding the mechanism(s) of sepsis-induced MODS is of paramount importance
to developing new therapeutic modalities. Unfortunately, the study of patients already in sepsis
is oftentimes complicated by a lack of proper case history, the presence of existing comorbidity,
and differences in septic stage. Moreover, people with sepsis are usually admitted to the
hospital during the terminal stages of sepsis which can make it extremely difficult to tease out
the mechanisms mediating sepsis progression. Given these and other ethical reasons, animals
have been widely used to study this disorder. Although there are several animal models of
sepsis currently in use, it should be noted that no one model adequately replicates the human
condition. Animal models of sepsis include:
7

1. Lipopolysaccharide injection
2. Injection of live bacteria
3. Cecal ligation and puncture (CLP)
4. Colon ascendens stent peritonitis (CASP)
5. Polymicrobial sepsis model
The injection of lipopolysaccharide (LPS) into animals to study the progression of sepsis
and its underlying mechanisms was first documented in the early 1970’s with the isolation of
endotoxin [29]. LPS is part of the outer membrane of gram-negative bacteria and is a primary
cause of host toxicity. The LPS molecule (Figure 2-2) consists of three distinct subunits- a)
outermost O-antigen b) a middle core region made of polysaccharide and c) an inner lipid A
portion that is highly conserved and a key cause of bacterial toxicity [30]. While the use of LPS
to understand the pathophysiology of sepsis has been vital to understanding SIRS, the LPS
model as a whole does not fully model the sepsis seen in humans. First, LPS does not represent
the whole bacteria and in addition, it does not explain why gram-positive bacteria, fungi, or
viruses can also cause sepsis. Secondly, there is a vast difference in the degree of response to
LPS between humans and animals. For example, studies have shown that the dosage of LPS in
mice has to be, on average, two hundred and fifty fold higher to produce the same degree of
cytokine response seen in humans [31]. Reasons for the discrepancy in the sensitivity to LPS to
provide the same degree of immune response in humans and rodents might probably be
attributed due to changes in balance of leukocyte subsets, NK inhibitory receptor families or
the toll receptors [32]. Thirdly, the clinical course of sepsis progression in humans is much
slower when compared with animal models [33].
8

Figure 2-2. Basic Structure of LPS

Source: Doi:10.1038/nrmicro1068

The injection of live bacteria into animals has paved the way for better understanding
the mechanisms behind host-pathogen interactions. Experiments performed using different
strains of bacteria, bacterial loads, loading types (bolus or slow and sustained release using
infusion pumps), and routes of administration (intraperitoneal, intravenous or subcutaneous)
where either one or several of these parameters were varied in different combinations have
greatly added to our knowledge on progression of sepsis. Nonetheless, like the LPS model, this
preparation has been widely criticized as it is thought that the injection of a single bacterial
strain poorly mimics the polymicrobial infections seen in humans and secondly, because the
9

injected bacteria oftentimes fail to colonize the host as is seen with a natural infection. To
overcome this barrier, studies employing polymicrobial agents have come into existence.
One of the first developed, and perhaps most common model of polymicrobial sepsis is
the cecal ligation and puncture (CLP) procedure. The CLP model is currently regarded as the
gold standard among all sepsis models [34]. This model involves ligation at ileocolic junction
followed by a single or multiple punctures to the cecum to control the severity of sepsis (Figure
2-3) [35]. This model of sepsis is highly favored among many investigators due to its ability to
manifest the hemodynamic changes seen in clinical conditions [36]. In addition, this model is
also thought to mimic the clinical presentation seen with abdominal trauma injuries.
Nonetheless, one major downfall of this model is a lack of repeatability within and between
different laboratories.

Figure 2-3. Model of cecal ligation and puncture

Source: DOI: 10.1016/j.ddmod.2011.10.002

A newer variation of the CLP model which is the colon ascendens stent peritonitis

(CASP) (Figure 2-4) model of sepsis was developed by Zantl and collagues [37]. In this
procedure, a stent is placed into the ascending colon which allows the passage of cecal
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contents into the peritoneal cavity. One significant advantage of the CASP model over the CLP
procedure is that this model is more rapid in eliciting an early and Toll like receptor -4 (TLR4)
driven immune response than one that is driven by TNF-α. Whether this newly developed
model will someday replace the older, and much more variable, CLP procedure as the model of
choice for sepsis research is still unknown.

Figure 2-4. Model of colon ascendens stent peritonitis

Source: DOI: 10.1016/j.ddmod.2011.10.002

The third model of polymicrobial sepsis, and perhaps the newest of all, is the cecal
inoculum procedure in which the cecal contents from a healthy donor animal are injected into
three or more other animals to induce the sepsis response [38]. A major advantage over the LPS
model is that this procedure uses a mixture of both gram positive and negative whole bacteria
instead of just the LPS molecule. In contrast with CLP and CASP, the degree of variability is
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minimized among animals as the amount of cecal material is fixed. Nonetheless, like all models,
disadvantages also exist with the cecal inoculum procedure. In particular, the bolus injection of
cecal contents creates a rapid immune response which differs from the presentation typically
seen in clinical cases.

2.5 Pathophysiology of sepsis
The pathophysiology of sepsis is a very complex process that begins with the entry of
the infectious agent into the body and its subsequent interaction with the host immune system
which results in release of inflammatory mediators. Overt stimulation of immune system results
in the excessive production of inflammatory mediators which include the cytokines,
chemokines, prostaglandins and other vasoactive substances. This initial response, if excessive,
can result in the systemic inflammatory response.
Activation of the immune system begins with the binding of LPS to the
lipopolysaccharide

binding

protein

(LPS-BP)

[39]

which

then

binds

to

CD14,

a

glycosylphosphatidylinositol-anchored protein [40] that helps in recognition of the LPS by TLR4MD2 complex [41]. Upon recognition of LPS, the TLR4 undergoes oligomerization to propagate
intracellular signaling via its adaptor proteins [42]. Downstream signaling is broadly divided into
either MyD88 dependent (TIRAP pathway) or MyD88 independent (TRAM pathway) pathways
(Figure 2-5). Upon stimulation of TLR4 by LPS, the Myd88 becomes activated and recruits IL-1
receptor-associated kinase-4 (IRAK-4) [43]. IRAK-4 then activates its downstream protein TRAF6
which forms a complex with ubiquitin conjugating enzymes and the subsequent activation of
TAK1. It is thought that TAK1 is responsible for the phosphorylation and activation of
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downstream IKK and MAPK proteins [44]. The activation of IKK leads to phosphorylation of IKB
alpha that removes the inhibitory effect on nuclear transcription factor NF-kB [45] which allows
it to translocate to the nucleus and cause the transcription of inflammatory cytokines [46].
The MyD88 independent pathway [47] involves the activation of TRAM via the TLR4-LPS
complex and the recruitment of downstream TRAF3 to IRF3. This recruitment is necessary for
late phase activation of NF-kB and MAPK proteins [48]. In addition, activation of IRF3 is also
necessary for the production of interferons [49] which are important defense mechanism
against both virus and bacteria [50].

Figure 2-5. Mechanism of LPS induced production of inflammatory mediators

Source: http://dx.doi.org/10.1016/j.cyto.2008.01.006

It is thought that inflammatory mediators released through the activation of
macrophages, neutrophils and other immune cells act in a paracrine and autocrine fashion on
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different cell types [51]. Cytokines can increase the generation of intracellular levels of ROS
through activation of NADPH oxidase or cause the synthesis of nitric oxide through induction of
iNOS gene expression [52-54]. Reactive oxygen species (ROS) can lead to impaired cell function
by activating or inhibiting proteins that are involved in cell signaling along with formation of
advanced glycation end products [55-57]. ROS can also cause peroxidation of lipids that affect
the integrity of cellular membranes [58] while nitric oxide reacts with superoxide and causes
formation of peroxynitrite [59] and protein nitrosylation [60]. In addition, nitric oxide can also
cause vessel vasodilation, hypotension, and marked circulatory impairment [61]. Although the
effects of ROS and inflammatory mediators are systemic, the degree of insult oftentimes varies
by organ.

2.6 Multi-organ dysfunction syndrome
The liver produces C-reactive protein, ceruloplasmin, ferritin, haptoglobin and
coagulation and complement factors as part of the acute inflammatory phase [62]. These
proteins are involved in xenobiotic opsonization, the entrapment of bacteria in blood clots and
the inhibition of iron uptake leading to inhibition of bacterial replication [63]. Also involved in
this acute response are the liver Kupffer cells which are responsible for a large portion of the
cytokines produced during sepsis and the phagocytosis of bacteria [64]. This cytokine release, if
excessive, can lead to impairments in glucose metabolism [65], decreased cytochrome p450
activity, and hepatic dysfunction [66]. Histologically, hepatic failure is characterized by
increased infiltration of polymorphonuclear (PMN) cells, centrilobular necrosis, sinusoidal
dilation, and hepatocyte congestion [67]. Coincident with these changes in tissue morphology,
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biochemical changes include increased levels of glutathione S transferase (GST), lactate
dehydrogenase (LDH), aspartate transaminase (AST) and alanine transaminase (ALT) [68].
While the liver is heavily involved in marshalling the acute response, the brunt of the
insult is most likely felt most by the kidney as it is highly susceptible to the hypoxia oftentimes
seen after changes in circulatory volume or severe vasodilation [69]. Within the kidneys, the
proximal tubules are more susceptible to sepsis induced hypoxic damage than the distal tubules
which can rely on glycolysis to provide energy [70]. Progressive renal failure is associated with
increased blood levels of blood urea nitrogen (BUN) and creatinine that can lead to systemic
organ failure [71]. Sepsis induced renal damage is histologically characterized by the loss of
tubular brush border, increased tubular dilatation and vacuolization. In some instances, renal
tubules also show the presence of sloughed endothelial cells. These changes result in
intratubular obstruction that can progress to complete renal failure [72].
Along with the renal system, the lungs also exhibit signs of inflammatory damage
through increased accumulation of neutrophils and monocytes that results in acute respiratory
distress syndrome (ARDS) [73]. ARDS is physiologically characterized by pulmonary edema,
arterial hypoxia and impaired excretion of carbon dioxide [74]. Accumulated PMN secrete
inflammatory cytokines and vasodilators that result in decreased velocity of blood flow and
impairment of the vascular endothelial barrier through the disruption of adherens junction
proteins such as VE-cadherin [75].

15

Figure 2-6. Mechanism of sepsis induced cardiac failure

Source: DOI: 10.1097/01.CCM.0000266683.64081.02

Finally, during the advanced stage of sepsis there are marked cardiovascular
complications including myocardial depression, impaired left ventricular diastolic function, and
reduced ejection fraction (Figure 2-6) [76-78]. The underlying causes of sepsis-induced cardiac
failure are multifactorial in nature but are usually attributed to the following: Increased
cytokines which cause myofibrillar destruction, high nitric oxide levels which result in systemic
hypotension, peroxynitrite formation and myofibrillar protein damage, infiltration of
monocytes, impaired oxygenation due to failure of the coronary circulation, and increased
prostaglandins which adversely affect coronary endothelial function. Histologically, sepsis
induced cardiac failure is typically characterized by contraction band necrosis and the presence
of increased sarcolemmal rupture [79].
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Figure 2-7. Schematic representation of sepsis induced multi-organ dysfunction

Source: DOI: 10.1097/01.CCM.0000282072.56245.91

2.6 Current therapies for sepsis
The clinical progression of sepsis in humans is usually characterized by an early
hyperdynamic phase that later transitions to a hypodynamic phase. The hyperdynamic phase is
characterized by increased body temperature, respiratory rate and hyperglycemia. Conversely,
the hypodynamic phase is associated with decreased body temperature, hypoglycemia and
marked hypotension. The 2013 Guidelines from the International Surviving Sepsis Campaign
suggest the following treatment strategy [80]:
1. Recognize sepsis
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2. Administer broad spectrum antibiotics and obtain blood and serum for microbial
culture and estimation of lactate levels.
3. Maintain blood pressure by administration of isotonic crystalloid fluids and achieve a
urine output of 0.5ml/kg/hr.
4. Administer vasopressor such as norepinephrine if the patient has not responded to
early fluid administration and if there is still a marked hypotension.
5. Finally measure patient’s blood oxygen saturation and try to identify the causes behind
its alteration and restore them to base values.
As a supportive treatment, a mild sedation without neuromuscular block can be indicated.
Similarly, the administration of insulin is advised if subsequent glucose readings measure above
180mg/dl and hemodialysis for renal failure patients are suggested [80]. While all the
therapeutic agents are geared towards minimizing the alterations in normal homeostasis, none
of them actually addresses the underlying causes for sepsis induced mortality.

2.7 Nanotechnology
Nanotechnology can be described as the manipulation of matter at atomic or molecular
scale to enhance its physical and chemical properties [81]. The word nanotechnology was first
coined by Dr. Norio Taniguchi to describe processes related to manufacture of semiconductors
[82]. The physical, chemical, and electro-magnetic properties of different substances can often
vary considerably at the nanoscale [83]. Researchers and industrialists are now exploiting these
properties for the design and manufacture of new therapeutic agents [84]. It is currently
estimated that more than 800 products that utilize nanoparticles are being manufactured by
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different companies [85]. Nanomedicine is an emerging branch of nanotechnology that is
concerned with the development of therapeutic drugs for diseases such as cancer, diabetes and
infectious diseases [86]. The most important contribution of nanomedicine is the development
of therapeutic drugs that have enhanced permeation and retention (EPR) effects which allow
them to successfully treat tumors that are inaccessible to commercial therapeutic agents [87].
In addition, recent animal studies have shown that the drugs designed through nanotechnology
can be used to treat atherosclerosis, prevent age-associated macular degeneration and
promote wound healing (Table 2-1) [88-90].
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Table 2-1. List of FDA approved nanomedicines

Source: http://www.uspharmacist.com/content/s/197/c/33020/

Currently, several types and formulations of nanoparticles are being investigated to
effectively treat several different pathological conditions. Nanoparticles made of gold, silver
platinum and cerium oxide have been used to treat breast cancer, viral infections, and diabetes
[91-93]. Multifunctional nanoparticles with increased stability, biocompatibility, and high
intracellular penetration that can deliver therapeutic drugs are being used in preclinical trials to
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treat cancer [94], for gene therapy [95], and for new types of multimodal imaging [96] (Figure
2-8). Generally, nanoparticles such as iron oxide nanoparticles coated with specific antibody are
used for targeted therapeutic approach as well as for diagnostic purposes.
Figure 2-8. Schematic image of a multifunctional nanoparticle

Source: Doi:10.1016/j.tibtech.2008.04.005

2.8 Cerium oxide nanoparticles and its prospective applications in medicine
Cerium oxide (CeO2) is a rare earth metal oxide with a fluorite lattice structure that can
cycle between oxidized (Ce+4) and reduced (Ce+3) states due to vacancies in the outermost
orbital shells (Figure 2-9) [17]. It is thought that the ratio of Ce+3/ Ce+4 determines the ability of
the CeO2 nanoparticles to act in the oxidation or reduction of other substances. One of the
main qualities that distinguishes CeO2 nanoparticles from other elements in the lanthanoid
series is the presence of partially filled subshells with electrons in orbitals 4f and 5d, which
makes it a potential tool for biomedical applications [97]. At the nanoscale, CeO2 nanoparticles
have increased chemical reactivity due to increase in surface to volume ratio. CeO 2
nanoparticles are used in the manufacture of cosmetics, polishing agents, diesel fuel additives,
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and fuel cells [98-100]. Investigation into the use of CeO2 nanoparticles for biomedical
applications is just beginning.
Recent data has suggested that CeO2 nanoparticles can inhibit the progression of
ovarian cancer by inhibition of angiogenesis without cytotoxic effects on different organs.
[101]. Arya and coworkers have shown that CeO2 nanoparticle treatment can attenuate cellular
ROS levels and protect primary cortical cells from apoptosis by acting to stabilize mitochondrial
membrane potential [102]. Estevez and colleagues have shown that CeO2 nanoparticles can
protect the mouse hippocampus from ischemic damage through reduction in levels of
superoxide and nitric oxide [103]. Similarly, other studies have shown that CeO2 nanoparticles
protect rodents from hypoxia induced oxidative stress [104] and that they can also protect
endothelial cells, cardiac progenitor cells and pancreatic islets against H2O2 induced oxidative
damage [15, 93, 100].

Figure 2-9. Structure of Cerium oxide (CeO2)

Source: http://en.wikipedia.org/wiki/Cerium(IV)_oxide
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Interestingly, researchers have also exploited the use of CeO2 nanoparticles as a potent
anti-infectious agent. Thill and coworkers were among the first to formulate the idea of using
CeO2 nanoparticles as an anti- bacterial agent against E.coli. In this work, they demonstrated
that the nanoparticles are positively charged at neutral pH which allows the particles to bind to
the negatively charged bacterial wall and induce bacterial cytotoxicity [18]. Independent studies
by other researchers have demonstrated similar findings for B.subtilis [105]. In addition to its
use as an anti-bacterial agent, other work has shown that CeO2 nanoparticles protect L929 cells
from the vesicular stomatitis virus by inhibiting its replication [106]. Whether CeO2
nanoparticles can function as an anti-infectious agent in vivo is still unclear and awaits
investigation.

2.9 Summary
Severe sepsis is a life threatening disease with high mortality rate. The symptoms of
sepsis are oftentimes confused with signs of general fever or flu making diagnosis difficult and
delaying the initiation of medical intervention. Current sepsis treatments have failed to
decrease the mortality rate as they are directed towards eliminating the bacteria but not the
inflammatory mediators generated through host-bacterial interaction. In vitro and in vivo
studies have shown that CeO2 nanoparticles exhibit potent anti-inflammatory, anti-oxidant and
anti-infectious properties [22, 107, 108]. Whether CeO2 nanoparticles can be used to treat
sepsis and its associated complications in vivo is not known.
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Chapter 3
The current chapter is focused on the hypothesis of this study and is set as three different
papers each corresponding to a specific aim as stated in chapter-1.
Paper-1
The following paper corresponds to specific aim-1 and deals with the hypothesis whether CeO2
nanoparticles can attenuate the systemic inflammatory response syndrome during septic insult
in male Sprague Dawley rats.
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Therapeutic applications of cerium oxide nanoparticles in treatment of polymicrobial sepsis
induced systemic inflammatory response syndrome and associated mortality

Running title- Treatment of sepsis induced systemic inflammatory response syndrome with
CeO2 nanoparticles.
Key words- Sepsis, cerium oxide nanoparticles, systemic inflammatory response syndrome,
interleukin-6
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Abstract
Sepsis is a disease of medical emergency that is characterized by severe oxidative stress
and system inflammation which leads to multi-organ failure and subsequent death. Cerium
oxide nanoparticles (CeO2) have been shown to exhibit anti-oxidant and anti-inflammatory
properties. This study tested whether administration of CeO2 nanoparticles could be beneficial
in the treatment of sepsis. Male Sprague-Dawley rats received a septic insult by intraperitoneal
injection of cecal inoculation (400 mg/kg). A single dose of CeO2 nanoparticles (3.5mg/kg) or
vehicle was administrated to rats immediately after cecal inoculation. Treatment of sepsis
animals with CeO2 nanoparticle significantly increased the survival rate along with decrease in
major inflammatory cytokine, interleukin-6. Treatment associated increases in animal survival
were associated with decreased serum KC/GROα, MIP1β, MDC, MCP3β, MIP3, Eotaxin, TIMP1,
myoglobin and blood urea nitrogen. Taken together, the findings of this preliminary study
indicate CeO2 nanoparticles may be useful as a therapeutic agent for treatment of sepsis.
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Background
Sepsis is associated with multiple-organ failure and is the leading cause of death in
critically ill patients [109]. Despite decades of clinical research, the incidence of sepsis and the
number of deaths resulting from sepsis continue to rise [110]. Current sepsis treatments are
largely supportive in nature and consist of antibiotics, NSAIDS, intravenous fluids, and
mechanical ventilator support where warranted [111]. Sepsis is characterized by a systemic
inflammatory state due to the overproduction of reactive-oxygen species (ROS) that appears to
be mediated, at least in part, by the activation of monocytes and macrophages. Indeed, it is
thought that macrophage derived nitric oxide (NO), tumor necrosis factor (TNF-α), interleukin
(IL)-1β and IL-6 play a major role in both the innate and acquired immune responses to bacterial
infection [112, 113].
Given the potential damaging effects of increased ROS on cellular structure and function
some have hypothesized that anti-oxidant drugs may be useful for the treatment of sepsis [114,
115]. To date, most in vivo interventional studies examining the effects of anti-oxidant
therapies have focused on the use of traditional pharmacological treatments [116, 117].
Although promising for certain applications, pharmacological intervention can be hindered due
to poor bio-distribution and the requirement of multiple daily dosing since each antioxidant
molecule is typically capable of scavenging only one free radical [118]. In an effort to overcome
these limitations, some researchers have begun investigations into the use of nanomaterials for
biomedical applications. Among the different nanomaterials under development, the use of
cerium oxide (CeO2) nanoparticles may be of particular interest. Cerium oxide is a rare earth
element of the lanthanide series which is widely used as an agent for ultraviolet absorption,
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oxygen sensing and automatic catalytic converters [119]. Cerium oxide appears to exhibit the
ability to transition between the Ce3+ and Ce4+ oxidative states which results in an auto
regenerative redox cycling [120]. Although biomedical applications still await analysis of
biocompatibility, recent data has indicated that these particles possess potent anti-bacterial
activity, anti-oxidant activity [18, 105], and cytoprotective properties [121-124].
Whether CeO2 nanoparticles can be used for the treatment of sepsis has, to our
knowledge, not been investigated. Therefore the purpose of this study was to investigate the
effect of CeO2 nanoparticle treatment on sepsis induced systemic inflammatory response
syndrome and associated mortality in a laboratory model of severe sepsis. Our findings suggest
that treatment with CeO2 nanoparticles may provide therapeutic benefit for the management
of polymicrobial sepsis.

Methods

Characterization of CeO2 nanoparticles
NanoActive CeO2 (99.9% purity as determined by ICP-MS; Lot #06-0118) was purchased
from NanoScale corporation (Manhattan, KS, USA). The stock suspensions were prepared in
deionized water by sonication using a Vibra Cell Sonicator (Sonics & Materials, Inc) at 600 W for
2 min at room temperature.
The hydrodynamic size and size distribution of CeO2 nanoparticles were evaluated in
deionized water using a Particle Size Analyzer (HORIBA, Model-LB-550) equipped with a He-Ne
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laser (633nm) using back scattered light. Experiments were performed utilizing triplicate runs
performed on three different days with freshly prepared samples.
Particles were imaged in their native state using a MultiMode-8, Atomic Force
Microscope (Bruker, Ewing, NJ) in the tapping mode. Briefly, a few drops of CeO 2 nanoparticles
were placed on freshly pealed mica substrate and allowed to dry in a petri dish floating in
sonicator water bath (VWR, 50D, Radnor, PA) for 30 min at 240 W. Images were recorded in
topography mode. Width and height measurements of adsorbed nanoparticles were made
using the microscope’s section analysis software.
For scanning electron microscopy, the particles were filtered with a 0.2 micron
nucleopore filter. The filters were then trimmed and one quarter was placed on an aluminum
stub with double-stick carbon tape. The sample was then sputter coated with gold/palladium
and viewed on a Hitachi S4800 field emission scanning electron microscope. For transmission
electron microscopy, the particles were diluted in double distilled filtered water and a drop was
placed on a formvar-coated copper grid to dry. The sample was viewed on a JEOL 1220
transmission electron microscope.

Induction of polymicrobial sepsis
Ninety two male Sprague-Dawley rats weighing 390-440 g were obtained from Hill Top
laboratories. Rats were housed two per cage and maintained in accordance with the guidelines
provided by the Marshall University Institutional Animal Care and Use Committee (IACUC), and
The Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) in a
12:12- h dark-light cycle at a temperature of 22 ± 2oC. Animals were provided food and water
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ad libitum, and acclimatized for at least 14 days prior to experimentation. The polymicrobial
sepsis procedure was performed as outlined previously [38]. Briefly, animals were randomly
assigned to one of four groups: sham control, CeO2 nanoparticle only, sepsis, and sepsis + CeO2
nanoparticle groups. After being anesthetized with ketamine HCL: xylazine (45 mg/kg / 5 mg/kg
i.p.) , the mid ventral surface is cleanly shaved and disinfected with 70% ethyl alcohol and a
small 0.5 cm vertical midline abdominal incision was made. Animals in the sepsis and sepsis +
CeO2 group received an i.p. injection of cecal inoculum (400mg cecal material/kg @ 5ml/kg in
5% dextrose water). The cecal inoculum was prepared by mixing cecal contents obtained from
donor rats. Fresh inoculum was prepared each day. The animals in control and sepsis group
received sterile 5% dextrose water @ 5ml/kg i.p. All incisions were closed with interrupted silk
sutures (3-0), and the abdomen was gently massaged to distribute the injectate. After the
surgical procedure, animals in sham control and sepsis groups received 100 µl of sterile distilled
water while animals in CeO2 and sepsis+CeO2 groups received 3.5 mg/kg of CeO2 nanoparticles
in 100µl of sterile distilled water via tail vein injection. All rats were given free access to food
and water after recovery from anesthesia. Animal survival was assessed for 14 days.
In other experiments, animals were randomly assigned to one of the four groups as
detailed previously. At 6 or 24 h after study initiation, animals were humanely sacrificed under
anesthesia and blood was collected by cardiac puncture. Serum was separated and used for
measuring various serum protein markers.
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Enzyme linked immunosorbant assay and multiplex immunoassay
ELISA was performed to determine the levels of serum IL-6. The cytokine interleukin-6
(IL-6) was analyzed in different groups using a reagent kit from BD Bioscience (Franklin Lakes,
NJ, USA) as outlined by the manufacturer. Multiplexed serum protein markers were analyzed
group wise by sending pooled samples to Rules-Based Medicine (Austin, TX, USA) using Rodent
MAP® version 3.0 antigen analysis with a Luminex 100 instrument, as described previously
[125].

Estimation of serum biochemical markers
Serum biochemical parameters were analyzed using an Abaxis VetScan® analyzer
(Abaxis, Union City, CA, USA). Briefly, 100ul of serum was loaded into each vetscan cartridge
and analyzed for changes in levels of serum albumin, alkaline phosphatase (ALP), alanine
transaminase (ALT), amylase, BUN, calcium, phosphorus, glucose, sodium, potassium, globulin
and total protein across different groups.

Statistical analysis
Results are presented as mean ± standard error of mean. For significant differences in
survival curves, log-rank test (Mantel-Cox) was performed using Prism 5.0 software (GraphPad
Software, La Jolla, CA). One-way analysis of variance (ANOVA) was used for comparison among
different groups followed by Student Newman Keuls post hoc test to determine statistical
significance using Sigmaplot 12 statistical software (Systat software Inc, San Jose, CA). A p-value
of < 0.05 was considered to be statistically significant.
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Results

CeO2 nanoparticle characterization
The mean hydrodynamic diameter of the CeO2 nanoparticles as determined by dynamic
light scattering (DLS) was 140 ± 52.9 nm (Figure 3-1, Panel A). AFM analysis indicated an
agglomerate size of 37.75 ± 3.8 nm width and 1.38 ± 0.28 nm height respectively (Figure 3-1,
Panel B). SEM and TEM analysis of CeO2 nanoparticles determined the size of individual CeO2
nanoparticles to be approximately between 20-40nm (Figure 3-1, Panels C, D).

CeO2 nanoparticles increased animal survivability in septic animals
Compared to control animals, the animals inoculated with the cecal material exhibited
several signs of shock including diarrhea, piloerection, and little or no spontaneous movement.
However, sepsis animals that are treated with CeO2 nanoparticles showed significant
improvement as seen by their alertness along with greater frequency in consumption of food
and water when compared to sepsis group alone. Furthermore treatment of the septic animals
with CeO2 nanoparticles increased animal survivability from ~25% to ~85% (Figure3-2).

CeO2 nanoparticles treatment decreased sepsis-induced systemic inflammation
Compared to controls, sepsis animals had increased serum IL-6 levels at 6 and 24 h
(P<0.05). CeO2 nanoparticle treatment decreased serum IL-6 levels at 6h by 66% when
compared with sepsis group (P<0.05) (Figure 3-3, Panel A). Although not significant, CeO2
nanoparticles also attenuated the sepsis induced increase in serum IL-6 at 24h. Similarly when
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compared to controls, sepsis animals showed higher levels of growth regulated alpha protein
(KC/GRO), macrophage inflammatory protein-1 beta (MIP-1 β) macrophage derived chemokine
(MDC), monocyte chemotactic protein-3 (MCP-3), myoglobin, macrophage inflammatory
protein-3 beta (MIP-3β), eotaxin, leptin, macrophage inflammatory protein-2 (MIP-2),
interferon gamma induced protein-10 (IP-10), tissue inhibitor of metalloproteinases-1 (TIMP-1)
and plasminogen activator inhibitor-1 (PAI-1) at 6 and 24 h (Figure 4A, 4B). However, treatment
with CeO2 nanoparticle diminished the levels of KC/GRO, MIP-1β, MDC, MCP-3, myoglobin MIP3β, eotaxin, leptin MIP-2, IP-10, and TIMP-1 by 1 – 3 fold (Figure 3-4, Panels A-D).
The levels of several other analytes including macrophage colony stimulating factor-1
(M-CSF-1), monocyte chemotactic protein-1 (MCP-1), stem cell factor (SCF), vascular
endothelial growth factor A (VEGF-A), IL-1α, IL-7, Il-11 and lymphotactin exhibited a trend
towards being increased with sepsis and decreased by at least one fold with CeO2 nanoparticle
treatment (Figure 3-4, Panels E, F).

CeO2 nanoparticles attenuated sepsis induced alterations in serum biochemical parameters
Sepsis is characterized by alterations in serum biochemical parameters such as BUN,
sodium, potassium and phosphorus. Treatment with CeO2 nanoparticles attenuated sepsis
induced increase in blood urea nitrogen and changes in sodium levels (Table 3-1) (p < 0.05).
Although not significant, CeO2 nanoparticle also attenuated sepsis induced changes in serum
alkaline phosphatase, amylase, phosphorus and potassium (Table 3-1).
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DISCUSSION
Despite decades of intensive investigation and significant advances in medical
technology, management of patient care and antimicrobial therapy, the overall mortality rate in
severe sepsis still remains unacceptably high [126]. The primary finding of this study was the
observation that a single injection of CeO2 nanoparticles, in the absence of antibiotic treatment,
fluid resuscitation, or other pharmacological intervention, was associated with a ~80% increase
in animal survivability in the cecal inoculum model of severe sepsis (Figure 3-2).
Previous studies have shown that the immune response to microbial insult is
characterized by release of large amounts of pro-inflammatory cytokines which lead to multiple
organ failure [127]. It is thought that elevations in serum IL-6 levels are highly correlated with
the survival of the septic patient [128, 129]. Similar to other reports using this model, our in vivo
studies showed that sepsis was associated with increased serum IL-6 levels [130] and
importantly, that our nanoparticle based treatment significantly attenuated these increases
(Figure 3-3). In addition to IL-6, it is also known that MODS is caused by other cytokines and
chemokines such as eotaxins, MCP-1, MCP-3, etc. [131]. Consistent with previous data
demonstrating that CeO2 nanoparticles can function as an antioxidant [132], the CeO2
nanoparticle treatment also appeared to attenuate the expression of the serum cytokine and
chemokine markers KC/GRO, MIP-1β, MDC, MCP-3β, myoglobin, MIP-3β, eotaxin, IP-10, and
leptin (Figure 3-4). Given that many of these cytokines, are derived from the liver Kupffer cells
these data suggest that our nanoparticle intervention is also capable of affecting macrophage
function.
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Sepsis is known to cause acute kidney injury (AKI) in about half of the infected
individuals and has a very poor prognosis in comparison with the patients without AKI [133].
Previous studies have shown that sepsis induced AKI is characterized by increased serum levels
of BUN and creatinine [134]. These changes are also accompanied by decreased sodium and
increased potassium levels [135]. Consistent with previous work, we found that blood urea
nitrogen (BUN) levels began to increase from 6 to 24 h, which is suggestive of kidney
dysfunction. However, treatment with cerium oxide nanoparticles attenuated the increase in
BUN at 6 h significantly (Table 3-1) (p<0.05). Although not statistically significant, cerium oxide
nanoparticles appeared to attenuate sepsis induced increases in BUN, sodium potassium and
phosphorus at 24 h time point. Similarly cerium oxide nanoparticles appear to increase serum
amylase and glucose levels that were attenuated by sepsis at 24 h (Table 3-1).

Conclusion
Sepsis is a state of severe whole body inflammation that rapidly progress to MODS
unless treated in time. Current therapeutic regime is largely ineffective in treating patients with
sepsis mainly due to the increasing antibiotic resistance along with the lack of a specific antiinflammatory drug that could attenuate SIRS. The main finding of the study is that a single dose
of cerium oxide nanoparticles attenuated sepsis induced mortality and SIRS along with serum
biochemical parameters in the absence of any supportive treatment. Future studies aimed at
the molecular mechanism of action of cerium oxide nanoparticles at the cellular level against
septic insult are warranted.
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Figures
Figure 3-1. Characterization of CeO2 nanoparticles.
CeO2 nanoparticles are characterized by A) DLS B) AFM C) SEM D) TEM
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Figure 3-2. CeO2 nanoparticles attenuated sepsis induced mortality.
(n=8/group).
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Figure 3-3. CeO2 nanoparticles attenuated sepsis induced increase in serum IL-6.
“*”Significantly different from control group, “$” significantly difference from CeO 2 group and
“#” significantly difference from sepsis group (p˂0.05). (n=6/group)
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Figure 3-4. CeO2 nanoparticles prevented sepsis induced SIRS by attenuating serum
inflammatory proteins.
(n=6/group).
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Tables
Table 3-1. CeO2 nanoparticles attenuated sepsis induced changes in serum biochemical parameters.
“*”Significantly different from control group, “$” significantly difference from CeO 2 group and “#” significantly difference from sepsis
group (p˂0.05). (n=6/group).
6h
Control

6h
Ceo2

6h
Sepsis

ALB

4.08±0.06

4.16±0.11

3.78±0.12$

ALP

195.00±19.96 196.25±20.78 160.88±15.22 176.13±25.47 265.88±22.02 238.13±36.40 91.29±4.83*$

ALT

77.63±6.83

Analyte

66.13±4.85

6h
Sepsis+Ceo2
3.86±0.04

54.38±2.52*

55.13±3.96*

24 h
Control

24 h
Ceo2

3.46±0.05

3.33±0.11

86.00±15.34 76.00±6.12

24h
Sepsis

24h
Sepsis+Ceo2

2.80±0.08*$

2.78±0.08*$

69.14±6.14

82.88±11.45

Amylase 920.25±30.64 874.50±17.90 1003.50±57.40 972.25±32.65 863.63±17.89 889.25±66.22 561.71±58.26
BUN

25.00±1.83

29.25±2.86

39.13±1.38

Ca+

10.75±0.26

10.60±0.22

10.91±0.22

Phos

11.41±0.79

10.70±0.58

13.86±0.73

*$

$

32.13±1.13

*#

17.88±0.90

18.88±2.89

71.43±13.40

10.478±0.18 10.50±0.14

10.50±0.19

10.19±0.08

11.78±0.89

9.35±0.21

10.77±0.87

9.89±0.26

113.44±6.05*$
*$

*$

790.56±108.41
41.22±5.60*$
10.11±0.21
9.41±0.40

*$

116.67±6.08*$

Glu

376.88±12.44 362.75±16.26 312.88±66.71 283.75±40.21 341.63±11.36 267.63±22.30 101.86±11.88

Na+

142.00±0.82 144.25±10.13 140.88±1.39

138.50±0.66$ 143.75±0.73 143.75±1.01 145.00±1.23

140.378±1.15#

K+

7.16±0.25

6.79±0.16

7.64±0.23

7.46±0.23

6.98±0.23

7.59±0.28

7.63±0.21

8.29±0.25

Glob

1.35±0.05

1.44±0.07

1.50±0.06

1.43±0.05

1.80±0.06

2.00±0.09

2.39±0.07

TP

5.41±0.04

5.60±0.09

5.26±0.08$

5.30±0.06$

5.28±0.05

5.31±0.08

5.19±0.13
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*$

2.34±0.07*$
5.13±0.09

Paper-2
The following paper corresponds to specific aim-2 and deals with the hypothesis whether CeO2
nanoparticles can attenuate severe sepsis-induced inflammatory damage to the heart and liver
during a septic insult in male Sprague Dawley rats.
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Therapeutic applications of anti-oxidant and anti-inflammatory properties of cerium oxide
nanoparticles in treatment of polymicrobial sepsis induced multi-organ failure

Running title- Treatment of sepsis induced multi-organ failure with CeO2 nanoparticles.
Key words- Sepsis, cerium oxide nanoparticles, cardiac failure, oxidative stress, inflammation
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Abstract
Sepsis is a life threatening disease that is associated with high mortality. Existing
treatments have failed to improve survivability in septic patients. The purpose of the present
study is to evaluate whether cerium oxide nanoparticles (CeO2) can prevent sepsis-induced
mortality by preventing cardiac and hepatic dysfunction in male Sprague Dawley rats.
Administration of a single dose (0.5mg/kg) of CeO2 nanoparticles intravenously to septic rats
significantly improved survival rates and functioned to restore core body temperature towards
baseline. Treatment-induced increases in animal survivability were associated with reduced
hepatic oxidative stress, diminished serum cytokines, and decreased serum chemokine levels.
Changes in serum inflammatory markers with treatment were accompanied by decreased
vascular leak along with reduced serum creatine kinase activity and myoglobin levels. In the
heart, treatment diminished ERK 1/2 MAPK- Stat-3 signaling and endothelial activation. Taken
together these data suggest that CeO2 nanoparticles can be used as a novel therapeutic agent
for treatment of polymicrobial sepsis.
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Introduction
Severe sepsis is a medical emergency that is caused by an excessive systemic
inflammatory response to bacteria, fungi, or other xenobiotic. Although easily managed if
caught early, diagnosis is often difficult due to non-specific symptoms which can result in
delayed treatment and the development of multiple organ failure, septic shock and death.
Standard treatment protocols advocate the administration of antibiotics in conjunction with
supportive therapy which is largely ineffective once sepsis has developed.
The cardiovascular failure that characterizes the latter stages of sepsis has been largely
attributed to the development of systemic hypotension due to severe vasodilatation and the
microvascular leak caused by the derangement of the endothelial barrier. As this stage
progresses, a state of depressed myocardial contractility occurs that oftentimes leads to
irreversible myocardial damage [136].
It is thought that much of the tissue damage seen in sepsis is caused by elevations in
tissue reactive oxygen species (ROS) and reactive nitrogen species (RNS) subsequent to the
increased release of cytokines that are a defining characteristic of the systemic inflammatory
response syndrome (SIRS). Recent data has suggested that the liver Kupffer cells are the
primary producer of the cytokines observed during SIRS [137]. Whether strategies designed to
quickly attenuate cytokine release by the Kupffer cells can diminish serum cytokine levels and
improve animal survivability following a lethal septic insult has, to our knowledge, not been
investigated.
Cerium is a lanthanide metal that can undergo redox cycling from Ce4+ (oxidized) to Ce3+
(reduced) states and is usually found in a complex with oxygen as CeO2. In nanoparticle form,
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CeO2 has been shown to function as a superoxide dismutase (SOD) mimetic [138], as a
preventive measure to combat hypoxia-induced oxidative stress [104], and to protect different
cell types against hydrogen peroxide-induced apoptosis [93, 100]. The use of CeO2
nanoparticles to prevent sepsis-induced cardiovascular dysfunction has, to our knowledge, not
been investigated.

Materials and Methods

Characterization of CeO2 nanoparticles
Cerium oxide nanoparticles were purchased from US Research Nanomaterials, Inc
(Houston, TX). Dynamic light scattering (DLS) was performed to estimate the mean size of CeO 2
nanoparticles in suspension using LB-550 DLS particle size analyzer (Horiba Scientific, Edison,
NJ). Naked particle size of the CeO2 nanoparticles was characterized by transmission electron
microscopy using JEOL JEM-2010 transmission electron microscope (TEM). X-ray diffraction
(XRD) was performed by Scintag XDS 2000 powder diffractometer. Scanning transmission
electron microscopy (STEM) images were acquired by the Aberration Corrected Analytical
Electron Microscope (TEM/STEM JEOL JEM-ARM200CF, Japan) operated at 200 keV. Electron
energy loss spectroscopy (EELS) data for CeO2 nanoparticles were collected by Gatan Enfina.

Induction of polymicrobial sepsis and therapeutic intervention
One hundred twenty eight male Sprague Dawley rats aged 10 weeks were purchased
from Hill-Top laboratories and housed in two-per cage at 22 ± 2°C with a 12:12 light-dark cycle
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for 2 weeks prior to experimentation. Animals were fed with standard rodent chow and had
access to food and water ad libitum. All surgical procedures were performed in accordance with
the guidelines provided by the Marshall University Institutional Animal Care and Use
Committee (IACUC), and The Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC). Briefly, animals were anesthetized under isoflurane and a small mid
ventral incision of 0.5 cm was made. Sham controls and CeO2 only groups were injected with
5ml/kg of 5% sterile dextrose solution intraperitoneally and the incision was closed with 3-0 silk
sutures. For the sepsis and sepsis+CeO2 groups, animals received a cecal inoculum of 600mg/kg
BW in 5ml/kg BW of 5% sterile dextrose solution intraperitoneally. Cecal material was obtained
from healthy rats and the material from each donor was used to induce sepsis in 4-5 rats. Sham
control and sepsis groups received 200 µl of sterile distilled water intravenously via tail vein
while the CeO2 and sepsis+CeO2 groups received CeO2 nanoparticles (0.5mg/kg) in 200 µl of
sterile distilled water intravenously. Rectal temperature was recorded at 0, 3, 6, 12, 18, 24, and
48h after receiving the cecal inoculum. Animals were observed for mortality for a period of 14
days.

Sample collection and estimation of organ ceria content
Whole blood was collected by cardiac puncture and centrifuged at 5,000 x g for 10 min
to collect serum at 3h and 18h time points. Animals were sacrificed under isoflurane anesthesia
and the heart and liver were excised and washed in Krebs–Ringer bicarbonate buffer (KRB) to
remove any blood, blotted to remove excess moisture, snap frozen in liquid nitrogen, and
stored at -80°C for further analysis.
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Frozen hearts and livers were sent to Elemental Analysis Inc. (Lexington, KY) for
estimation of ceria content by induction coupled plasma-mass spectrometry (ICP-MS) as
described elsewhere [125].

Estimation of immune cell number and serum markers of inflammation
The number of white blood cells (WBC), neutrophils, monocytes and lymphocytes were
estimated in whole blood and peritoneal fluid collected at 3h and 18h time points using an
Abaxis VetScan HM2 hematology analyzer (Abaxis, Union city, CA). Peritoneal fluid was
obtained only from sepsis and sepsis and sepsis + CeO2 groups. Total serum ROS/RNS was
measured using OxiSelect™ in vitro ROS/RNS assay kit (Cell Biolabs, Inc., San Diego, CA) as
outlined by the manufacturer. Creatine kinase activity was measured in serum using a creatine
kinase fluorometric assay kit (Cayman Chemical Company, Ann Arbor, MI) as directed by the kit
instructions.
Serum and peritoneal fluid samples from each of the different groups (n=6/group)
collected at 3h and 18h time points were pooled and sent to Myriad RBM (Austin, TX) for the
analysis of serum growth factors, cytokines and markers of inflammation using rodent MAP® V.
3.0. Pooled samples were run in triplicate for statistical analysis.

Liver histology and superoxide levels
Liver tissue was sectioned (4µm) using Leica CM1950 cryostat onto poly-L-lysine coated
slides. Visualization of hematoxylin and eosin staining was performed to evaluate liver
morphology using Evos XL microscope (Life technologies, Grand Island, NY).
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Levels of hepatic superoxide were estimated using dihydroethidium stain (Life
technologies, Grand Island, NY). Briefly, liver sections were washed with PBS for 5 min and
stained with 5µM solution of dihydroethidium for 1h at room temperature in the dark. Tissue
sections were imaged using Evos FL microscope (Life technologies, Grand Island, NY) after PBS
washing (3 x 5 min) and the levels of superoxide were estimated by image analysis using image
J analysis software.

SDS-PAGE and immunoblotting
Approximately 100 mg of frozen tissue was taken and pulverized in liquid nitrogen and
added to 900ul of T-PER (Pierce, Rockford, IL, USA) containing 1% protease and phosphatase
inhibitors (P8340 and P5726, Sigma- Aldrich, St. Louis, MO, USA). Samples were homogenized
and centrifuged at 13,000 rpm for 10 min at 4°C to collect the supernatant. Amount of protein
in the samples was estimated through 660 nm assay (Pierce, Rockford, IL, USA) and normalized
with T-PER and 4x Laemlli buffer to a final equal concentration across all samples. Equal amount
of protein was loaded in 10% PAGEr Gold Precast gel (Lonza, Rockland, ME) and transferred to
nitrocellulose membranes using standard protocol as detailed elsewhere [139]. Membranes
were block with 5% milk in TBST for 1h at room temperature, washed thrice with TBST and
probed for detection of ERK 1/2 MAPK , p-ERK 1/2 MAPK (Thr202/Tyr204), Stat-3, p-Stat-3
(Tyr705), GAPDH (Cell Signaling Technology, Danvers, MA), P-selectin, VCAM-1, nitrotyrosine
(Abcam, Cambridge, MA) and iNOS (Santa Cruz, Dallas, TX). Membranes were incubated with
primary antibody overnight at 4°C, washed with TBST (3 x 5 min), and incubated with
secondary anti-rabbit (Cell Signaling Technology, Danvers, MA) or anti-mouse antibody (Santa
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Cruz, Dallas, TX) for 1 h at room temperature. Immunoreactive signal was visualized using
Supersignal West Pico Chemiluminiscent substrate (Pierce, Rockford, IL, USA) and quantified
using Fluorchem 9900 software (Protein Simple, Santa Clara, CA). Protein expression was
normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Statistical analysis
Results are presented as mean ± SEM. The log-rank test (Mantel-Cox) was performed
using Prism 5.0 software (GraphPad Software, La Jolla, CA) to determine differences in animal
survivability between groups. A two way analysis of variance using Tukey’s multiple comparison
was performed where appropriate to evaluate differences in core temperature amongst the
different groups. Differences in groups with equal sample size were evaluated by one way
analysis of variance using Student Newman Keuls or Dunn’s post hoc analysis for samples with
unequal size. A one way ANOVA by ranks with Kruskal Wallis post hoc analysis was used for
samples with non-normal distribution and a simple t-test was performed where appropriate
using Sigmaplot 12 statistical software (Systat software Inc., San Jose, CA) to test for the
presence of significant differences between groups. A probability value of P < 0.05 was
considered to be statistically significant.
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Results

Characterization of CeO2 nanoparticles
The mean hydrodynamic diameter of CeO2 nanoparticles as estimated through dynamic
light scattering experiments was found to be approximately 90nm (Figure 3-5, Panel A). TEM
and STEM –HAAF analysis determined the size of individual nanoparticles to be approximately
between 10-30nm (Figure 3-5, Panels B, C). The high resolution image of the CeO2 nanoparticle
shows that the atoms of CeO2 are highly ordered (Figure 3-5, Panel D) and the EELS data (Figure
3-5, Panel F) confirms the existence of the Ce and O element. XRD was used to demonstrate
cubic fluorite structure of CeO2 nanoparticles as seen through typical peaks (Figure 3-5, Panel
G).

Effect of CeO2 nanoparticles on sepsis induced mortality and hypothermia
Nanoparticle treatment decreased sepsis mortality from 100% to ~25% (Figure 36, Panel A, P < 0.05).

Improvement in survivability was associated with a significant

improvement in core body temperature from 18h (Figure 3-6, Panel B, P < 0.05).

Nanoparticle treatment increased liver ceria and decreases systemic oxidative stress
Compared to untreated animals, liver ceria content was increased in the animals
receiving nanoparticle injections (Table 3-2). Nanoparticle treatment decreased sepsis-induced
increases in total serum ROS levels (Figure 3-6, Panel C, P < 0.05).
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Nanoparticle treatment decreased sepsis induced hepatic damage, tissue ROS and iNOS levels
Histological analysis of the livers obtained from control animals revealed normal hepatic
and sinusoidal morphology. Nanoparticle treatment diminished sepsis-induced sinusoidal
dilatation and hepatocyte congestion (Figure 3-7, Panels A-D). Consistent with the histological
findings, tissue superoxide levels were increased with sepsis and decreased with nanoparticle
treatment (Figure 3-7, Panels E-I, P < 0.05). In a similar fashion, nanoparticle treatment also
decreased sepsis induced increases in hepatic iNOS (Figure 3-8, Panel A, P<0.05) and protein
nitrosylation at 3h (Figure 3-8, Panel B, P < 0.05).

Nanoparticle treatment modulated sepsis related cytokines, chemokines and growth factors
Nanoparticle treatment reversed sepsis-induced changes in several inflammatory
chemokines (Table 3-3), cytokines (Table 3-4), and other inflammation related proteins (Table
3-5, P < 0.05). Consistent with these data, nanoparticle treatment also decreased sepsis
induced increases in the hepatic damage markers GST-α and GST-Mu (Table 3-5, P < 0.05).

CeO2 nanoparticles reduced cardiac Jak-Stat and endothelial cell activation
Sepsis increased and nanoparticle treatment decreased the phosphorylation of ERK 1/2
(Figure 3-9, Panel A, P < 0.05) and Stat-3 (Figure 3-9, Panel C, P < 0.05). These changes in
protein phosphorylation were accompanied by treatment associated decreases in P-selectin
(Figure 3-9, Panel E, P < 0.05) and VCAM-1 in the septic animals at 3 and 18 h respectively
(Figure 3-9, Panel F, P < 0.05).
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Nanoparticle treatment decreased indices of sepsis induced cardiac muscle damage
Sepsis increased and nanoparticle treatment decreased serum creatine kinase activity at
18 h (Figure 3-10, Panel A, P < 0.05). Similarly, nanoparticle treatment decreased sepsis induced
increases in circulating myoglobin levels at 3 h and 18 h (Table 3-5, P < 0.05).

Cerium oxide nanoparticles modulated the inflammatory response in the peritoneum by
decreasing the recruitment of immune cells
The number of circulating WBC, lymphocytes, monocytes and granulocytes was not
changed with sepsis or nanoparticle treatment. Conversely, nanoparticle treatment reduced
sepsis induced increases in the number of peritoneal lymphocytes and monocytes at 18 h
(Table 3-6, P < 0.05).

Discussion
Despite decades of extensive research the sepsis induced mortality rate remains
unacceptably high. The primary aim of this work was to evaluate whether CeO2 nanoparticles
are protective against sepsis induced organ damage and death in the Sprague Dawley rat. To
test this possibility, we utilized a polymicrobial model of severe sepsis that is characterized by
100% mortality. Compared to the untreated controls, we found that a one-time CeO2
nanoparticle intervention was able to decrease the mortality rate to only 25% (Figure 3-6).
To explore the mechanistic basis of this finding, we determined where the injected CeO2
nanoparticles may accumulate. Previous work has shown that injected CeO2 nanoparticles
exhibit a proclivity to preferentially collect in the spleen, liver, kidneys, and lungs [17].
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Consistent with these data, we found significantly higher amounts of CeO2 nanoparticles in the
liver compared to that observed in the heart (Table 3-2). To examine if the CeO2 nanoparticles
were able to protect the liver against a septic insult, we next examined if treatment was
associated with improvements in liver morphology. Our histological studies demonstrated that
sepsis caused hepatic sinusoidal dilatation and congestion of hepatocytes which appeared to be
decreased with CeO2 nanoparticle treatment (Figure 3-7). At the cellular level, sepsis is
characterized by an increase in ROS and RNS which leads to cellular protein damage through
carbonylation, nitrosylation or formation of AGE products [140-142]. Studies have shown that
CeO2 nanoparticles act as a free radical scavenger in addition to accelerating the decay of
peroxynitrite which can induce protein nitrosylation [22, 143, 144]. As expected from our
morphological analysis, we found that sepsis increased hepatic superoxide production, systemic
ROS levels, and iNOS expression and importantly, that these changes were attenuated with
nanoparticle treatment (Figures 3-7, 3-8).
Given that the liver is thought to be the primary source for the excessive inflammatory
state seen with sepsis [145], we next sought to determine if the morphological changes we
observed were also associated with modulation of the hepatic inflammatory response.
Interestingly, we found that the CeO2 nanoparticle treatment attenuated sepsis induced
alterations in several different types of chemokines, cytokines, growth factors and
inflammatory proteins (Tables 3-3, 3-4, 3-5). Of particular importance, we found that the CeO2
nanoparticle treatment functioned to attenuate sepsis-induced increases in serum GST-α and
GST-mu which are characteristic of hepatic damage (Table 3-5). In addition, we also found that
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the levels of the inflammatory cytokine IL-6 and LIF were also significantly decreased with
treatment (Table 3-4).
Previous studies have shown that IL-6 and LIF can bind to gp130 to cause activation of
the Jak-Stat pathway [146, 147]. Other work has shown that the phosphorylation of ERK 1/2 can
lead to activation of Stat-3 that can cause increased transcription of several inflammatory
mediators [148, 149]. Here we show that sepsis led to activation of Jak-Stat pathway in the
failing heart. Treatment with CeO2 nanoparticles attenuated the activation of the ERK 1/2-JakStat pathway (Figure 3-9). Moreover, studies have shown that Stat-3 signaling in the heart can
cause increased microvascular permeability by increasing the expression of ICAM-1 and VCAM1 [150]. It is thought that the increased expression of ICAM-1 and VCAM-1 on the endothelium
is one of the priming events for recruitment of macrophages and neutrophils into myocardium
which can lead to increased microvascular permeability [151]. Consistent with our finding of
decreased ERK 1/2-Jak-Stat activation, we found that nanoparticle treatment attenuated sepsis
induced increases in VCAM-1 expression (Figure 3-9). To explore the possibility that this
treatment induced decrease in endothelial activation was associated with diminished vascular
leakiness, we next examined the effect of the nanoparticle intervention on the accumulation of
inflammatory cells in the peritoneal cavity. As expected, we found that the treated animals
exhibited decreases in the number of peritoneal monocytes and lymphocytes (Table 3-6).
Finally, we next asked if treatment might decrease sepsis induced cardiac muscle damage.
Creatine kinase and myoglobin have been used in various pre-clinical and clinical studies as
markers of cardiac damage [152-156]. We found that the treated animals had less serum
creatine kinase activity and myoglobin levels than the untreated septic animals (Figure 3-10,
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Table 3-5). While this study provides mechanistic insight into how the administration of CeO2
nanoparticles might protect against a septic insult further experiments examining other organs
and organ systems are likely warranted.

Conclusion
Our data suggest that a single dose of CeO2 nanoparticles in the absence of antibiotics or
fluid resuscitation, or other supportive treatment can significantly decrease animal mortality in
a severe sepsis model. This increase in animal survivability was associated with modulation of
the hepatic inflammatory response (Figure 3-11).
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Figures
Figure 3-5. Characterization of CeO2 nanoparticles.
CeO2 nanoparticles are characterized by A) DLS B) TEM C) STEM-HAAF D&E) STEM F) EELS G)
XRD
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Figure 3-6. Nanoparticle treatment decreased sepsis induced mortality, animal hypothermia
and total serum ROS levels.
A) Survival curve. B) Temperature. Control (n=8), CeO2 (n=8), Sepsis (n=16), Sepsis+CeO2 (n=16).
*P<0.05 compared to control group, # P<0.05 compared to sepsis group and $ indicates that
the last known temperature of dead sepsis animal has been used in consecutive time points for
statistical purposes. C) Effect of nanoparticle treatment on total serum ROS levels (n=6/group).
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared
to sepsis group
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Figure 3-7. Effect of CeO2 nanoparticles on sepsis induced hepatic inflammatory damage.
H&E staining of 18h time point liver sections imaged at 200X magnification A) Control B) CeO 2
C) Sepsis D) Sepsis+CeO2. Dihydroethidium staining of 18h time point liver sections imaged at
200X magnification E) Control F) CeO2 G) Sepsis H) Sepsis+CeO2 and I) Quantification of
superoxide levels in different groups. *P<0.05 compared to control group, $ P<0.05 compared
to CeO2 group and # P<0.05 compared to sepsis group. (n=4/group).
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Figure 3-8. Effect of CeO2 nanoparticles on sepsis induced hepatic nitrosative stress.
A) Levels of iNOS as determined by western blotting and normalized to GAPDH. B) Levels of
nitrotyrosine as determined by western blotting and normalized to GAPDH. *P<0.05 compared
to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group.
(n=6/group).
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Figure 3-9. Effect of CeO2 nanoparticles on sepsis induced cardiac inflammation.
A & B) Levels of phosphorylated and total ERK1/2 as determined by western blotting and
normalized to GAPDH respectively. C & D) Levels of phosphorylated and total Stat-3 as
determined by western blotting and normalized to GAPDH respectively. E) Levels of P selectin
as determined by western blotting and normalized to GAPDH F) Levels of VCAM-1 as
determined by western blotting and normalized to GAPDH. *P<0.05 compared to control group,
$ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group).
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Figure 3-10. Cerium oxide nanoparticles attenuated sepsis induced serum creatine kinase
activity.
*P≤0.05 compared to control group, $ P≤0.05 compared to CeO2 group and # P≤0.05 compared
to sepsis group. (n=6/group).
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Figure 3-11. Schematic representation of mechanism of action of CeO2 nanoparticles against
polymicrobial sepsis induced MODS and death.
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Tables
Table 3-2. Levels of ceria content in heart and liver as determined through ICP-MS.
Results are presented as mean ± SEM. N=3/group.

Organ

Control
3h

Heart

Liver

CeO2 3h

Sepsis
3h

Sepsis +
CeO2 3h

Control
18h

<LLOQ

<LLOQ

<LLOQ

<LLOQ

<LLOQ

12.00±0.76
ppm

<LLOQ

9.07±0.08
ppm
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Ceo2 18h

Sepsis
18h

Sepsis + CeO2
18h

<LLOQ

<LLOQ

<LLOQ

<LLOQ

<LLOQ

10.67±0.17
ppm

<LLOQ

12.00±0.28
ppm

Table 3-3. Effect of CeO2 nanoparticles on sepsis induced serum chemokines.
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared
to sepsis group. (n=6/group).
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Serum

Peritoneal fluid

Analyte

Eotaxin (pg/mL)
Growth-Regulated
Alpha Protein
(ng/mL)
MacrophageDerived Chemokine
(pg/mL)
Macrophage
Inflammatory
Protein-1alpha
(ng/mL)
Macrophage
Inflammatory
Protein-1 beta
(pg/mL)
Macrophage
Inflammatory
Protein-2 (pg/mL)
Monocyte
Chemotactic
Protein 1 (pg/mL)
Monocyte
Chemotactic
Protein 3 (pg/mL)
Monocyte
Chemotactic
Protein-5 (pg/mL)
T-Cell-Specific
Protein RANTES
(pg/mL)

Sham control
3h

CeO2 3h

362.33±1.76

354.67±8.29

0.06±0.00

0.04±0.00

938.00±18.56

995.67±27.42

Below LLOQ

Below LLOQ

268.67±16.15

261.67±9.13

25.67±1.20

20.67±1.33

897.33±16.50

848.00±17.95

723.00±21.00

655.67±17.05

Below LLOQ

Below LLOQ

1.10±0.00

1.04±0.06

Sepsis 3h

*

*

1273.33±28.48

CeO2 18h

808.33±41.79

349.33±5.55

Below LLOQ

Below LLOQ

1039.67±32.46

711.00±5.20

Below LLOQ

Below LLOQ

199.00±30.83

128.33±7.97

23.33±2.33

Below LLOQ

1483.33±42.56

973.00±19.66

1009.00±23.97

597.67±12.55

#

Below LLOQ

Below LLOQ

#

1.43±0.03

0.74±0.01

*

856.00±14.47

$

3.50±0.06

Sham control
18h

Sepsis + CeO2 3h

*$

1483.33±26.03

2.57±0.03

*$#

*$#

*

*$

$

1553.33±31.80

4.20±0.20

6.37±0.17

3003.33±92.07

*

$

*$

2270.00±65.06

2016.67±6.67

*$

3.70±0.17
*$

215.00±2.65

*$#

*

$

*

*$

4766.67±93.87
#

318.33±7.26

2.50±0.06

#

*

*$

2240.00±75.06

*$

1700.00±30.55
#

1.98±0.42

2.10±0.06
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*

Sepsis 18h

Sepsis + CeO2
18h

1866.67±26.03

1020.00±5.77

*$

*$#

5.23±0.07

2.20±0.06

4410.00±55.68

2500.00±60.0

*$

1413.33±71.26

416000.00±13
576.94

493666.67±252
08.02

43933.33±276
0.64

32533.33±1502.

179333.33±66
6.67

169000.00±929
1.57

125333.33±31
79.80

146000.00±568

*$#

Below LLOQ

Below LLOQ

Below LLOQ

4.37±0.03

3.20±0.12

3

*$

0
*

1740.00±17.32

#

5896.67±61.7

2903.33±121.7

*$

*$

2.30±0.00

*

#

2650.00±45.0
*$#

3333.33±14.5
3

Below LLOQ

*$#

257.00±6.08

9

3600.00±34.64

#

21633.33±1039.
76

8486.67±225.8

*

#

24433.33±896.
91

*$#

6.70±0.29

654.33±10.71

3716.67±131.70

16.67±0.33

20.67±0.67

*$

2636.67±71.72

Sepsis + CeO2
18h

23.33±0.33

0

6

*

#

Sepsis 18h

1.60±0.00

*$#

#

#

59

6.24

#

#

Table 3-4. Effect of CeO2 nanoparticles on sepsis induced serum cytokines.
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group).

Serum
Analyte

Sham
control 3h

CeO2 3h

Sepsis 3h

Sepsis + CeO2 3h

Interferon gamma
(IFN-gamma) (pg/mL)

Below LLOQ

Below LLOQ

102.33±5.78

67.00±8.00

Interferon gamma
Induced Protein 10 (IP10) (pg/mL)

42.33±2.60

40.67±2.85

192.33±4.98

Interleukin-6 (IL-6)
(pg/mL)

Below LLOQ

Below LLOQ

7.50±1.00

Interleukin-12 Subunit
p70 (IL-12p70) (ng/mL)

0.13±0.03

0.12±0.02

Leukemia Inhibitory
Factor (LIF) (pg/mL)

Below LLOQ

Below LLOQ

Oncostatin-M (OSM)
(ng/mL)

0.37±0.01

0.32±0.01

Tumor Necrosis Factor
alpha (TNF-alpha)
(ng/mL)

0.10±0.02

Below LLOQ

*

Peritoneal fluid

Sham
control 18h

CeO2 18h

Sepsis 18h

Sepsis + CeO2
18h

Sepsis 18h

Sepsis + CeO2 18h

#

36.67±9.21

Below LLOQ

46.67±14.33

38.33±9.74

48.67±2.19

15.67±0.67

*$#

48.33±3.71

28.33±0.67

22.67±0.88

16.33±0.33

4.97±0.27

Below
LLOQ

Below LLOQ

5.27±0.67

Below LLOQ

36.33±1.76

13.67±0.33

*$

Below LLOQ

Below
LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

0.09±0.01

0.06±0.01

Below LLOQ

Below LLOQ

Below
LLOQ

Below LLOQ

1520.00±30.00

Below LLOQ

12000.00±321.46

7616.67±141.93

*$#

0.42±0.04

Below LLOQ

0.94±0.03

19.33±1.76

27.67±1.33

#

Below
LLOQ

Below LLOQ

0.14±0.01

0.39±0.01

0.34±0.01

0.28±0.02

0.81±0.05

*$

*$

0.22±0.01

*

153.33±5.55

0.66±0.03

0.13±0.01$
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*

117.00±1.73

*$

*

91.67±2.67

*$#

*#

0.73±0.02

0.14±0.01

#

#

#

#

#

#

#

Table 3-5. Effect of CeO2 nanoparticles on sepsis induced serum growth factors and other proteins related to inflammation.
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group).
Serum
Analyte

Sham
control 3h

CeO2 3h

Fibroblast
Growth Factor
9 (ng/mL)

3.82±1.27

3.87±0.38

10.20±0.42

Leptin (ng/mL)

0.44±0.02

0.43±0.02

0.75±0.01

Myeloperoxida
se (ng/mL)

11.00±0.58

11.33±0.33

30.67±0.88

Myoglobin
(ng/mL)

1153.33±12.
02

1373.33±31.

Sham control
18h

CeO2 18h

*$#

5.37±0.47

2.52±0.54

*$#

0.27±0.01

0.25±0.01

2.97±0.15

25.67±0.33

25.00±0.58

39.33±0.67

*$#

1086.67±31.80

1186.67±17.
64

Glutathione STransferase
alpha (ng/mL)

54.00±2.00

30.33±1.67*

69.33±2.19*$

42.67±3.93*$
#

62.67±2.60

35.00±1.53*

2126.67±56.67*
$

147.00±1.53*$#

Glutathione STransferase Mu
(ng/mL)

376.33±20.2
0

Below LLOQ

228.33±37.44*

173.33±25.43
*

232.00±0.00

Below LLOQ

14133.33±328.3
0*

764.67±40.53

Vascular
Endothelial
Growth Factor
A (pg/mL)

Below LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

459.00±12.70

296.67±31.33

*
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Sepsis + CeO2
3h

Peritoneal fluid

Sepsis 3h
*$

*$

0.68±0.02

*$

3083.33±23.33

7.60±0.26

*$

24.00±0.58

*

Sepsis 18h
11.67±0.33

*$

*$

#

1546.67±20.2
8
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*$

*$

6220.00±200.75
*$

Sepsis + CeO2 18h

Sepsis 18h

Sepsis + CeO2 18h

*$#

2.90±0.12

1.83±0.20

#

10.00±0.00

10.00±0.00

*$#

16433.33±970.
11

11600.00±305.51

1004.33±22.41

756.67±15.45

213.33±11.78

138.00±6.56#

#

10666.67±272.
84

5830±245.02

#

5563.33±149.4
8

5763.33±79.65

9.43±0.38

1.83±0.07

34.00±0.00

3246.67±52.39

*$#

#

#

#

#

Table 3-6. Effect of CeO2 nanoparticles on sepsis induced changes in immune cells.
$ P<0.05 compared to CeO2 group, # P<0.05 compared to sepsis group. (n=5-9/group).

Whole Blood

Peritoneal Fluid

Cell Type
Control 3h

CeO2 3h

Sepsis 3h

Sepsis +
CeO2 3h

Control 18h

CeO2 18h

Sepsis 18h

Sepsis +
CeO2 18h

Sepsis 18h

Sepsis + CeO2
18h

WBC (10 /L)

2.156±0.689

1.410±0.331

1.406±0.235

2.158±0.652

2.821±0.385

2.124±0.330

2.106±0.439

2.612±0.486

27.045±2.357

24.506±6.031

Lymphocytes
9
(10 /L)

0.946±0.321

0.887±0.362

0.646±0.094

1.292±0.356

1.194±0.253

0.959±0.245

1.266±0.314

1.514±0.335

3.191±0.441

1.756±0.382

Monocytes (10 /L)

0.060±0.0193

0.0117±0.003

0.120±0.031

0.092±0.055

0.126±0.041

0.191±0.034

0.0256±0.010

0.191±0.075

2.766±0.385

1.440±0.513

Granulocytes
9
(10 /L)

1.153±0.418

0.540±0.159

0.640±0.148

0.778±0.314

1.504±0.349

0.973±0.090

0.025±0.09

0.910±0.142

21.091±1.981

19.124±4.318

9

9
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#
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Paper-3
The following paper corresponds to specific aim-3 and deals with the hypothesis whether CeO2
nanoparticles can attenuate severe sepsis-induced inflammatory damage to the kidney during a
septic insult in male Sprague Dawley rats.
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Cerium oxide nanoparticles attenuate polymicrobial sepsis induced acute kidney injury

Running title- Treatment of sepsis induced AKI with cerium oxide nanoparticles

Key Words- Cerium oxide nanoparticles, sepsis, kidney injury molecule-1, cystatin-C, oxidative
stress
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Abstract
Sepsis is the leading cause of death in non-cardiac intensive care units. Sepsis-induced
acute kidney injury (AKI) is a complicating morbidity that is associated with poor prognosis.
Herein, we examined whether treatment with cerium oxide (CeO2) nanoparticles can reduce
AKI in a severe polymicrobial sepsis model that causes severe microvascular leak that leads to
deficit in circulatory volume and subsequent development of AKI. Administration of a single
dose of CeO2 nanoparticles (0.5mg/kg) to male Sprague Dawley rats attenuated sepsis-induced
tubular dilatation and the loss of brush border. These changes in renal structure were
accompanied by decreases in sepsis-induced renal oxidative stress, stat-3 phosphorylation, and
caspase-3 cleavage which are suggestive of diminished kidney inflammation and apoptosis. At
the systemic level, CeO2 nanoparticle treatment reduced sepsis-induced increases in serum
levels of kidney injury molecule-1 (KIM-1), cystatin-C, osteopontin, β-2 microglobulin, vascular
endothelial growth factor-A (VEGF-A), blood urea nitrogen (BUN), potassium, sodium, and
circulating glucose levels. Taken together, these data suggest that CeO2 nanoparticles may help
to prevent the development of AKI during severe sepsis.
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Introduction
Severe sepsis is characterized by an overwhelming immune response that is often
associated with acute kidney injury (AKI). Sepsis-induced AKI is thought to be primarily caused
by the increased levels of reactive oxygen species (ROS) that are typically seen during the
systemic inflammatory response syndrome (SIRS) that proceeds the development of frank
sepsis [157, 158]. AKI is associated with damage to renal tubular cells, cellular apoptosis,
increased tubular permeability, the loss of brush border [159] and increased tubular dilatation
[72]. AKI is a serious complication which is associated with increased morbidity and poor
prognosis [133]. Despite improvements in medical technology, current treatment modalities
are largely supportive in nature and do little to address underlying causes.
Recent advances in nanotechnology have allowed the development of new compounds
that can effectively scavenge ROS [160-162]. One such compound is cerium oxide (CeO2) which
when formulated in nanoparticle form, may be useful for the treatment of inflammation [163],
diabetes [93, 164], cancer [165, 166], and ischemic stroke [103]. Herein, we examined the
therapeutic efficacy of using CeO2 nanoparticles for the treatment of sepsis-induced AKI. On
the basis of previous data demonstrating that CeO2 nanoparticles can function to scavenge ROS,
we hypothesized that CeO2 nanoparticle treatment would be associated with decreased renal
oxidative stress and sepsis-induced damage.
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Materials and Methods

Characterization of CeO2 nanoparticles
CeO2 nanoparticles were commercially purchased from US Research Nanomaterials, Inc.
(Houston, TX). Atomic force microscopy was performed to estimate the mean particle size.
Briefly, 20 μl of CeO2 nanoparticles was placed on freshly cleaved mica (V1 mica, SPI Inc, West
Chester, PA) incubated for 15 minutes, rinsed with deionized water and dried under nitrogen.
Nanoparticles were imaged in noncontact mode at a frequency of 319 kHz and a scan speed of
0.5 Hz using a Nano-R microscope (Pacific Nanotechnology Inc., Santa Clara, CA) equipped with
a TM300A noncontact probe (SensaProbes, Inc., Santa Clara, CA). The size of the CeO2 particles
was characterized by a JEOL JEM-2010 transmission electron microscope.

Polymicrobial sepsis induction and CeO2 nanoparticle treatment
Seventy two male Sprague Dawley rats aged 10 weeks were purchased from Hill-Top
laboratories and allowed to acclimatize for 2 weeks prior to experimentation. All surgical
procedures were performed in accordance with the guidelines provided by the Marshall
University Institutional Animal Care and Use Committee (IACUC), and The Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC). Briefly, animals were
anesthetized under isoflurane and a small mid ventral incision of 0.5 cm was made. Sham
controls and CeO2 only groups were injected with 5ml/kg of 5% sterile dextrose solution
intraperitoneally (i.p.) while sepsis and sepsis+CeO2 groups

received cecal inoculum of

600mg/kg BW in 5ml/kg BW of 5% sterile dextrose solution i.p. Cecal material was obtained
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from healthy rats that served as donors. Sham control and sepsis groups were injected with 200
µl of sterile distilled water intravenously (i.v.) while the CeO2 and sepsis+CeO2 groups received
CeO2 nanoparticles (0.5mg/kg) in 200 µl of sterile distilled water i.v. via the tail vein at the time
of sham surgery or sepsis induction.

Tissue collection
Animals from different sets were humanely sacrificed under isoflurane anesthesia at 3h
and 18h after sepsis induction and the kidneys were excised, the capsule removed and were
washed in Krebs–Ringer bicarbonate buffer (KRB) to remove any blood. Kidneys were frozen in
liquid nitrogen and stored at -80°C for further analysis. Serum was obtained from whole blood
through cardiac puncture by centrifugation at 5,000 x g for 10 min at room temperature.

Renal histology and staining for F-actin
Frozen kidneys were sectioned (4µm) with a Leica CM1950 cryostat and transferred to
poly-L-lysine coated slides. Hematoxylin and eosin staining was performed using a Histoperfect
kit (BBC biochemical, Seattle WA) to assess kidney morphology and imaged using an Evos XL
microscope (Life Technologies, Grand Island, NY). Renal sections were also stained for F-actin
using rhodamine phalloidin (Life Technologies, Grand Island, NY) as detailed elsewhere [167].
Briefly, frozen sections were washed with PBS and then fixed in 4% methanol free
formaldehyde for 10 min. After a PBS wash (3 x 5 min), sections were permeabilized with 0.3%
Triton X-100 in PBS for 20 min, washed with PBS (3 x 5 min) and then blocked with 1% BSA for
30 min. Actin was stained by incubation of the tissue sections with 0.165 µM rhodamine
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phalloidin for 20 min in the dark. After washing (3 x 5 min in PBS), tissues were mounted and
imaged using an Evos FL microscope (Life Technologies, Grand Island, NY) before quantifying
the fluorescence intensity using Image J analysis software.

Estimation of renal superoxide levels
Levels of superoxide in renal sections were estimated using dihydroethidium staining
[168]. Superoxide indicator dihydroethidium exhibits blue fluorescence under normal
conditions, but exhibits a bright red fluorescence when oxidized and intercalates with DNA.
Briefly, sections were washed with PBS and incubated with 5mM dihydroethidium for 1 h at
room temperature in the dark. Sections were washed with PBS (3 x 5 min) and imaged with an
Evos FL microscope (Life Technologies, Grand Island, NY). Mean fluorescence intensity was
determined using Image J analysis software.

SDS-PAGE and immunoblotting
Approximately 100 mg of frozen kidney was pulverized to a fine powder and then
homogenized in 900ul of T-PER (Pierce, Rockford, IL, USA) containing protease and phosphatase
inhibitors. Homogenates were centrifuged at 5,000 g x 10 min at 4°C to collect the supernatant.
The 660nm protein assay (Pierce, Rockford, IL, USA) was used to determine the amount of
protein in each sample. Samples were equally diluted with 4x Laemlli buffer, separated using
SDS-PAGE on 10% PAGEr Gold Precast gels (Lonza, Rockland, ME) and then transferred to
nitrocellulose membranes as detailed elsewhere [139]. Membranes were blocked with 5% milk
in TBST for 1 h before being probed with antibodies against p-Stat-3 (Tyr 705), Stat-3, cleaved
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caspase 3 and caspase 3 (Cell Signaling Technology, Danvers, MA). After washing (3 x 5 min
TBST), membranes were incubated with secondary anti-rabbit antibody (Cell Signaling
Technology, Danvers, MA). Immunoreactivity was visualized using Supersignal West Pico
Chemiluminiscent substrate (Pierce, Rockford, IL, USA) before quantification using Fluorchem
9900 software (Protein Simple, Santa Clara, CA).

Multiplex immunoassay and serum biochemical analysis
Serum samples from different animals in each group were pooled and sent to Myriad
RBM (Austin, TX) for the analysis of KIM-1, cystatin-C, osteopontin, β-2 microglobulin and VEGFA using rodent kidney multiplex immunoassay (MAP). Pooled samples were run in triplicate for
statistical analysis. Levels of glucose, BUN, sodium and potassium were determined in serum
using an Abaxis VetScan® analyzer (Abaxis, Union City, CA, USA).

Statistical analysis
Results are presented in the form of mean ± standard error of mean. Differences
between groups were determined using a one way analysis of variance (ANOVA) with Student
Newman Keul’s post hoc analysis, an ANOVA on ranks with Student Newman Keul’s post hoc
analysis for non-normally distributed samples or the Students t-test where applicable. A
probability value of P < 0.05 was accepted as statistically significant.

Results
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Characterization of nanoceria
CeO2 nanoparticle size as determined using AFM was approximately 30 nm (Figure 3-12,
Panel A). Analysis by scanning electron microscopy and transmission electron microscopy
demonstrated a particle size of 10 – 40 nm (Figure 3-12, Panels B, C). Energy dispersive X-ray
spectroscopy analysis of ceria and oxygen content was 80.4% and 16.36%, respectively (Figure
3-12, Panel D).

Nanoparticle treatment decreased serum indices of renal failure during sepsis
Compared to the control animals, sepsis increased the levels of β-2 microglobulin at 3 h
and 18 h. Similarly, sepsis was also associated with increased levels of KIM-1, cystatin-C,
osteopontin, and VEGF-A at 18h. CeO2 nanoparticle treatment attenuated sepsis-induced
increases in KIM-1 cystatin-C, osteopontin, β-2 microglobulin, and VEGF-A at the 18 h time
point (Table 3-7, P < 0.05). In a similar fashion, treatment also decreased sepsis-induced
increases in blood glucose, BUN, and potassium (Table 3-8, P < 0.05).

Cerium oxide nanoparticles attenuated sepsis induced renal damage and breakdown of
tubular F-actin
Sepsis-induced AKI was characterized by renal tubular dilatation, a loss of the brush
border and damage to the glomerular capillary network. These alterations in renal structure
were attenuated with treatment (Figure 3-13, Panels A-H). In addition to changes in gross
morphology, sepsis was also associated with a marked loss of F-actin in the proximal tubular
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cells (Figure 3-14, Panel C) which was attenuated with nanoparticle treatment (Figure 3-14
Panels D, E, P < 0.05).

Cerium oxide nanoparticles attenuated sepsis induced oxidative stress, prevented Stat-3
activation and cleavage of caspase 3
Nanoparticle treatment decreased sepsis-induced increases in renal superoxide levels
(Figure 3-15, P < 0.05), Stat-3 activation (Figure 3-16 Panel A, P < 0.05) and the cleavage of
caspase-3 at 18h (Figure 3-16, Panel B, P < 0.05).

Discussion
Although increases in serum levels of creatinine have been considered to be a
traditional biomarker for AKI, recent data has suggested that sepsis-induced AKI may exhibit a
distinct pathophysiology from that seen in non-septic AKI [169]. One of the distinguishing
features between non-septic AKI vs septic AKI is the presence of non-hemodynamic
mechanisms of cellular injury as result of immunological, toxic and inflammatory factors in
sepsis. On the basis of these data, and others demonstrating that sepsis-associated decreases in
creatinine production may limit the use of this molecule as a marker for AKI [170], we chose to
examine how sepsis may affect the regulation of KIM-1, β-2 microglobulin, cystatin-C, and
osteopontin. Kim-1 was chosen as it is thought to be a biomarker for proximal tubular injury
[171] while β-2 microglobulin was selected as it has been shown to be a reliable indicator of
marker for functional status of proximal tubular cells [172]. Similarly, we also chose to examine
cystatin-C as it has been shown to be a reliable surrogate for the assessment of glomerular
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filtration rate [173] while osteopontin is thought to be a marker of macrophage and neutrophil
infiltration [174]. Consistent with our histopathological findings, we found that sepsis-induced
increases in the levels of β-2 microglobulin, KIM-1, cystatin-C and osteopontin were attenuated
with CeO2 nanoparticle treatment (Table 3-7).
In addition to changes in renal structure, sepsis has also been shown to affect the serum
content of several renal metabolites and ions. Increases in blood urea nitrogen levels are a
byproduct of protein metabolism with subsequent decrease in renal function. With sepsis, BUN
levels have been shown to be increased due to decrease in circulatory volume as a result of
marked vasodilation and microvascular leak. Consistent with this, we also found that sepsis
increased serum BUN levels and importantly that these increases were diminished with
nanoparticle treatment (Table 3-8). Similarly, sepsis has also been found to cause elevations in
serum glucose levels [175]. Although not fully understood, it has been postulated that the
development of hyperglycemia is associated with increased insulin clearance along with
elevation in plasma levels of cortisol and glucagon that promote hepatic gluconeogenesis [176].
While elevation in glucose levels is an adaptive response to meet metabolic demands of the
body such as wound healing, it is also shown that hyperglycemia causes predisposition to
multiple complications such as neuropathy and MODS [177]. Supporting our analysis of serum
BUN, we also found significant increases in serum glucose in the septic animals and that
treatment appeared to attenuate the serum glucose levels. In addition to alterations in serum
metabolites it is known that sepsis can also affect the concentration of serum Na+ / K+ ions.
Indeed, hyponatremia and hyperkalemia are generally found in acute renal failure with
decreased renal tubular flow rate [135]. Similar to previous studies we found that sepsis caused
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a decrease in serum levels of sodium [178] and increase in potassium, which were attenuated
with CeO2 nanoparticle treatment (Table 3-8).
Sepsis-induced AKI is characterized by increases in tissue ROS which are thought to be
the cause of the renal inflammation, tubular dilatation, vacuolization, and loss of brush border
that characterize this disorder [179, 180]. We observed similar findings in the present study and
importantly, also found that CeO2 nanoparticle treatment appeared to attenuate these changes
in the kidney. Specifically, we found that CeO2 nanoparticles attenuated sepsis induced loss of
brush border in proximal tubular cells and also attenuated tubular dilatation. Moreover,
treatment with CeO2 nanoparticles also improved renal glomerular integrity when compared to
sepsis group (Figure 3-13).
To extend upon these findings, we next sought whether CeO2 nanoparticles can protect
the kidney against sepsis-induced decreases in F-actin. AKI is characterized by loss of F-actin
that leads to disruption in cytoskeleton network and impairs renal structural and functional
integrity [167]. Consistent with our other assessments of renal function and morphology, we
found that sepsis caused a significant decrease in loss of F-actin and importantly that
nanoparticle treatment appeared to attenuate these changes (Figure 3-14). Taken together
with our analysis of renal function, these data suggest that the CeO 2 nanoparticle treatment
functioned to improve both kidney structure and function.
We next sought to understand how the CeO2 nanoparticles may have prevented sepsisinduced changes at the molecular level. Sepsis is characterized by increases in oxidative stress
that result in uncontrolled SIRS and multi-organ failure [181]. Studies have shown that CeO2
nanoparticles are potent ROS scavengers and that they can function as catalase and SOD
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mimetics [17]. To investigate this possibility, we next examined how sepsis and nanoparticle
treatment affected renal superoxide levels. Consistent with the effects of treatment on renal
structure and function, we found that CeO2 nanoparticle administration significantly decreased
sepsis-induced elevations in renal superoxide oxide levels (Figure 3-15).
Given the role that inflammation plays in the pathogenesis of sepsis, we next evaluated
the Janus kinase signal transduction (Jak-Stat) pathway. The Jak-Stat pathway is one of the
principal signaling mechanisms for a wide variety of cytokines and growth factors that are
thought to be important in regulating the renal remodeling and fibrosis [182-185]. Consistent
with these data, we found that sepsis was associated with the activation of Stat-3 in the kidney
at 18hand importantly, that this activation was attenuated with nanoparticle treatment (Figure
3-16). Whether this decrease in Stat-3 phosphorylation is due to treatment induced decreases
in the amount of circulating cytokines or increased activation of intracellular phosphatases is
currently unclear and will require further investigation.
In addition to inflammation, a growing body of evidence suggests that the apoptosis of
renal tubular cells is a major causes for AKI in sepsis [186]. Studies have shown that the
activation of Jak-Stat pathway in renal tubular cells results in tubular cell death through caspase
3 activation [183]. Other studies have shown that cleavage of caspase-3 is also responsible for
the activation of gelsolin which has F-actin severing properties [187]. It is thought that the loss
of F-actin is associated with cytoskeletal derangement that can lead to apoptotic cell death and
development of AKI [167]. Supporting our F-actin data, we observed that sepsis was associated
with evidence of increased caspase-3 cleavage at 18h. Similar to our other data, this finding
appeared to be abrogated following nanoparticle treatment (Figure 3-16).
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Conclusion
Taken together, the results of the current study demonstrate that a single dose of CeO 2
nanoparticles confers protection against severe sepsis induced acute kidney injury. Although
not fully understood, our data suggest that the protective effect of the CeO 2 nanoparticles
appears to be related to their ability to scavenge reactive oxygen species which prevents
caspase-3 mediated loss of F-actin and renal tubular cell damage. Further investigation to
better understand the pharmacological potential of CeO2 nanoparticles for the treatment of
sepsis induced AKI may be warranted.
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Figures
Figure 3-12. Characterization of CeO2 nanoparticles.
CeO2 nanoparticles are characterized by A) AFM, B) SEM, C) TEM, D) EDS
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Figure 3-13. CeO2 nanoparticles attenuated sepsis induced renal damage.
Hematoxylin and eosin staining of 18h time point kidney sections A) Control B) CeO 2 C) Sepsis D)
Sepsis+CeO2 (imaged at 200X magnification) E) Control F) CeO2 G) Sepsis H) Sepsis+CeO2
(imaged at 400X magnification) (n=4/group).
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Figure 3-14. CeO2 nanoparticles attenuated sepsis induced loss of F-actin.
Rhodamine phallodin staining for F-actin of 18h time point kidney sections imaged at 200X
magnification A) Control B) CeO2 C) Sepsis D) Sepsis+CeO2 and E) Relative fluorescence intensity
as a measure of F-actin. *P<0.05 compared to control group, $ P<0.05 compared to CeO2 group
and # P<0.05 compared to sepsis group. (n=3/group).
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Figure 3-15. CeO2 nanoparticles attenuated sepsis induced renal superoxide levels.
Dihydroethidium staining of 18h time point kidney sections imaged at 200X magnification A)
Control B) CeO2 C) Sepsis D) Sepsis+CeO2 and E) Quantification of superoxide levels in different
groups. *P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05
compared to sepsis group. (n=4/group).
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Figure 3-16. CeO2 nanoparticles attenuated sepsis induced renal inflammation and apoptosis.
A) Levels of phosphorylated to total Stat-3 as determined by western blotting. B) Levels of
cleaved to total caspase 3 as determined by western blotting. *P<0.05 compared to control
group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group).
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Tables
Table 3-7. CeO2 nanoparticles attenuated sepsis induced increases in biomarkers of AKI.
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group).
Serum
Analyte

Sham
control 3h

CeO2 3h

Sepsis 3h

Sepsis +
CeO2 3h

Sham
control 18h

CeO2 18h

Sepsis 18h

Sepsis + CeO2
18h

Beta-2Microglobulin
(µg/mL)

54.0 ± 3.0

49.7 ± 2.4

76.0 ± 1.5*$

77.3 ± 1.8*$

52.0 ± 3.5

32.7 ± 1.5*

128.0 ± 5.9*$

78.3 ± 7.2*$#

Cystatin-C
(ng/mL)

578.7 ± 14.3

633.0 ±30.6

686.0 ± 14.5

690.3 ± 42.1

699.7 ± 52.7

555.3 ± 41.6

1890.0 ± 62.5*$

1093.3 ± 37.6*$#

KIM-1
(ng/mL)

Below LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

3.3 ±0.13

2.5 ± 0.1#

Osteopontin
(ng/mL)

10.8 ± 1.2

11.0 ± 0.6

11.0 ± 0.6

12.3 ± 0.3

9.7 ± 0.0

7.9 ± 0.2*

72.3 ± 4.8*$

36.3 ± 1.8*$#

VEGF-A
(pg/mL)

Below LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

Below LLOQ

459.0 ± 12.7

296.7 ± 31.3#

90

Table 3-8. CeO2 nanoparticles attenuated sepsis induced alterations in serum biochemical parameters.
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group).
Serum
Analyte

Sham
control 3h

Sepsis + CeO2
3h

Sham
control 18h

CeO2 18h

Sepsis 18h

Sepsis +
CeO2 18h

CeO2 3h

Sepsis 3h

Glucose

284.0 ± 8.1

262.3 ± 10.1

426.9 ±
19.7*$

308.6 ± 22.6#

245.3 ± 13.3

290.6 ± 17.3*

105.5 ± 8.5*$

125.3 ± 5.1*$

Blood urea
nitrogen

22.0 ± 1.1

21.0 ± 1.0

29.9 ± 2.0*$

24.71±1.17#

19.2 ± 0.5

18.5 ± 0.9

71.3 ± 7.2*$

57.4 ± 3.1$

Sodium

142.4 ± 0.7

142.9 ± 0.9

136.8 ± 1.4*$

140.1 ± 0.5#

142.0 ± 1.2

141.6 ± 0.9

138.8 ± 0.8

140.6 ± 0.5

Potassium

5.9 ± 0.4

5.4 ± 0.1

6.4 ± 0.3

6.3 ± 0.2

5.6 ± 0.2

5.8 ± 0.3

7.8 ± 0.2*$

7.1 ± 0.2*$#
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Chapter 4
Discussion
Sepsis is the leading cause of death globally in spite of intense research efforts and
recent advance in medical care [188]. The complex pathophysiology of sepsis in conjunction
with growing antibiotic resistance is likely to further worsen the prognosis of septic patients.
Although not fully understood, it is thought that the uncontrolled systemic inflammatory
response that characterizes the transition from sepsis to multiple organ dysfunction syndrome
(MODS) is the primary cause of septic associated death [181].
Over the past decade, the field of nanotechnology has seen immense growth and it has
played a vital role in the continued growth of several different manufacturing sectors [84, 189].
More recently, nanotechnology has also begun to be used for biomedical applications where
the unique properties of nanomaterials can be exploited for diagnostic and even therapeutic
uses [190, 191]. As an example, and of particular relevance to this research, CeO2 nanoparticles
are currently being tested for the detection of lactate levels and chronic inflammation [192],
the treatment of radiation-induced damage [193], ovarian cancer [166] and stroke [194].
The main objective of the current study is to evaluate whether CeO 2 nanoparticles can
be used to prevent sepsis induced MODS and death. To accomplish this objective, this study
was divided into two different sub-projects. In the first, we examined whether CeO2
nanoparticles could be used to protect Sprague Dawley rats from moderate sepsis induced SIRS.
Once completed, we then undertook the second aspect of this study where we examined if
CeO2 nanoparticles could be used to prevent against severe sepsis induced MODS. Our findings
are summarized as follows:
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Effect of CeO2 nanoparticles on sepsis induced hypothermia and mortality
Sepsis is characterized by high mortality rates that are closely associated with decreased
core body temperature [195]. Previous studies have shown that the sepsis-induced cytokine
response is associated with increased levels of TNF-α, IL-1β and prostaglandins which function
to alter the hypothalamic set point causing hypothermia [196]. Coincident with the release of
cytokines, other work has shown that sepsis also causes the release of the potent vasodilator
nitric oxide which can cause the loss of heat from the peripheral circulation [197]. In the current
study, we found that the induction of moderate sepsis in male Sprague Dawley rats results in
mortality rate of 75% while severe sepsis results in 100% mortality rate. We also observed that
decreases in core body temperature in the severely septic animals were closely associated with
the death of the animal. Treatment with the CeO2 nanoparticles reduced the mortality rate to
~17% in animals with moderate sepsis and to 25% in animals with severe sepsis. Treatment
induced increases in survivability were found to be associated with the restoration of core body
temperature towards baseline.

Effect of CeO2 nanoparticles on sepsis induced systemic inflammatory response
It was previously thought that the sepsis induced mortality was a result of direct
microbial insult. More recently, additional data has suggested that sepsis-induced mortality is
more likely to be caused by the uncontrolled immune response that characterizes the
development of MODS [198]. Similar to previous studies, we found that both moderate and
severe sepsis resulted in increased levels of serum and peritoneal fluid inflammatory cytokines,
chemokines and growth factors. These increases in systemic inflammation were attenuated
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with CeO2 nanoparticle treatment. Consistent with these data, other work has also suggested
that CeO2 nanoparticles can also modulate cellular ROS levels / inflammation [199]. How
treatment with CeO2 nanoparticles might function to decrease cellular ROS levels /
inflammation in vivo is currently unclear and will require further study.

Effect of CeO2 nanoparticles on sepsis induced multi-organ dysfunction syndrome
Previous studies have shown that the sepsis-induced inflammatory cytokine storm leads
to MODS and death [200]. It is thought that much of the circulating cytokines seen during the
cytokine storm are released by the resident macrophages, Kuppfer cells, of the liver [201].
Similar to other studies, we found that the intravenous injection of CeO 2 nanoparticles lead to
their highest accumulation in liver but not in other organs [17]. We next sought to evaluate
whether CeO2 nanoparticles can modulate oxidative and nitrosative stress. As expected, CeO 2
nanoparticles attenuated sepsis-induced hepatic superoxide levels along with protein
nitrosylation. In addition, CeO2 nanoparticles also attenuated GST-α and GST-mu which are
hallmarks of hepatic damage. We next examined whether CeO2 nanoparticles can prevent
sepsis induced cardiac failure and found that CeO2 nanoparticles attenuated serum myoglobin
levels and creatine kinase activity along with attenuation in cardiac ERK1/2-Jak-Stat pathway
and decreased expression of VCAM-1. In addition, we also found that CeO2 nanoparticles
attenuated sepsis-induced increases in renal damage markers BUN, KIM-1, cystatin C,
osteopontin and β-2 microglobulin. Histologically, CeO2 nanoparticles attenuated sepsisinduced tubular dilatation, the loss of brush border, and improved F-actin levels in the kidney.
These changes were associated with decrease in Stat-3 activation and cleavage of caspase 3.
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Taken together, the data from the current study suggest that CeO2 nanoparticles protect
against sepsis-induced organ damage by modulating the hepatic inflammatory response.
Summary
1. CeO2 nanoparticles significantly improve survivability in male Sprague Dawley rats
against moderate and severe septic insults.
2. Improvement in survival rate is associated with the restoration of core body
temperature towards baseline.
3. CeO2 nanoparticles specifically accumulate in the liver and modulate the hepatic
inflammatory response to septic insult.
4. CeO2 nanoparticles attenuate hepatic damage by decreasing sepsis-induced oxidative
and nitrosative stress which is associated with improvements in hepatic morphology.
Modulation of the hepatic inflammatory response by CeO2 nanoparticles is associated
with decreased levels of systemic inflammatory mediators.
5. CeO2 nanoparticles in conjunction with decreased cytokine release from the liver appear
to protect the heart during sepsis by attenuating the activation of the inflammatory ERK
1/2-Jak-Stat pathway.
6. Nanoparticle treatment is associated with evidence of decreased sepsis-induced cardiac
damage and microvascular leak.
7. CeO2 nanoparticles attenuate sepsis-induced alterations in serum myoglobin and
creatine kinase activity levels.
8. CeO2 nanoparticles attenuate sepsis-induced AKI by preserving the structural integrity
and F-actin.
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9. CeO2 nanoparticles attenuate sepsis-induced increases in renal oxidative stress and
apoptosis by inhibition of Stat-3 and cleavage of caspase 3.

Figure 4-1. Schematic representation of mechanism of action of CeO2 nanoparticles against
severe sepsis induced MODS and death.
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Future directions
The present study provides a first glimpse detailing the potential protective effects of
CeO2 nanoparticles against sepsis induced MODS and death. While the study is novel, the
limitation of the study is that we tested the effects of the co-administration of CeO2
nanoparticles at the time of sepsis induction. It is unlikely that this situation models a realworld clinical situation where sepsis is diagnosed prior to the initiation of treatment. Similarly,
the animals used in this study did not suffer from comorbidities which is often seen in clinical
settings. To address these shortcomings, further studies based on the following specific aims
may be warranted.
Specific Aim I:
Severe sepsis is a complex pathophysiological process in which the host immune system
becomes deregulated leading to organ failure. Early stages of systemic septic insult are
characterized by the activation of circulating macrophages and neutrophils that cause the
release of pro-inflammatory mediators such as TNF- α and IL-1β [202]. These cytokines then
activate the resident macrophages such as Kupffer cells in liver, mesangial cells in kidney and
dust cells in lungs. Because the liver is the primary organ for the synthesis of acute phase
proteins and it also contains the largest number of resident macrophages, it may be useful to
determine whether CeO2 nanoparticles can prevent cytokine induced activation of Kupffer cells.
While the current study found that CeO2 nanoparticles accumulate in the liver, it is still unclear
whether CeO2 nanoparticles modulate Kupffer cell activation. To specifically address this
question, Kupffer cells from livers of animals injected with CeO2 nanoparticles could be isolated
and analyzed for the presence of ceria content through ICPMS and electron microscopy. Finally
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to determine whether CeO2 nanoparticles can inhibit Kupffer cell activation, the determination
of mRNA expression for various inflammatory cytokines in Kupffer cells across different groups
may be warranted.
Specific Aim II:
The sepsis mortality rate is higher in neonatal children and the elderly due to an
underdeveloped or compromised immune system [203]. The current study was performed in
adult male Sprague Dawley rats where their innate and adaptive immune system has
completely developed. Whether CeO2 nanoparticles are efficacious for the treatment of the
very young or the aged has not been investigated.
Previous studies in conjunction with this current study have demonstrated that CeO 2
nanoparticles exhibit the ability to scavenger ROS [11]. Unlike traditional anti-oxidants or antiinflammatory agents that are rapidly metabolized and eliminated, CeO2 nanoparticles do not
undergo any metabolic change and may persist in the body for a long period of time [204]. In
addition, the autocatalytic property of CeO2 nanoparticles is thought to allow repeated cycling
of Ce+4 to Ce+3 which may allow the particles to scavenge ROS indefinitely [118]. As such,
studies investigating a second septic insult weeks after the initial one is resolved in the absence
of subsequent treatments may be useful to better understand the true potential of using CeO2
nanoparticles to treat sepsis.
Specific Aim III:
Findings from the current study demonstrate that CeO2 nanoparticles protect male
Sprague Dawley rats against severe sepsis when administered at the time of sepsis induction.
However, most cases of deaths are seen in people that are admitted to the hospital at late or
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final stages of sepsis where most of the irreparable damage has already been done. As such,
studies investigating the therapeutic potential of CeO2 nanoparticles by post-administration of
nanoceria several hours after sepsis induction may be warranted.
Finally, another major drawback to the current therapeutic regime aimed for the
treatment of sepsis is the presence of comorbidity. Studies have shown that patients with
preexisting conditions such as chronic renal failure or heart failure have a poorer prognosis
following sepsis induction than those that do not [205]. As such, it may be of use to explore if
post-administration of CeO2 nanoparticles can prevent sepsis induced MODS and mortality in
individuals that have pre-existing diseases.
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